WO2014124191A1 - Reduced sodium food product - Google Patents
Reduced sodium food product Download PDFInfo
- Publication number
- WO2014124191A1 WO2014124191A1 PCT/US2014/015192 US2014015192W WO2014124191A1 WO 2014124191 A1 WO2014124191 A1 WO 2014124191A1 US 2014015192 W US2014015192 W US 2014015192W WO 2014124191 A1 WO2014124191 A1 WO 2014124191A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- food product
- alkyl
- compound
- compounds
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 **C(C(C1O)O*)OC(*)C1O Chemical compound **C(C(C1O)O*)OC(*)C1O 0.000 description 12
- CWWWHACKSNBBMU-UHFFFAOYSA-N CCCC(CCc1ccccc1)=O Chemical compound CCCC(CCc1ccccc1)=O CWWWHACKSNBBMU-UHFFFAOYSA-N 0.000 description 2
- JHJPDDBIHSFERA-UHFFFAOYSA-N COc(cc(CCC(CC(CCc1ccccc1)=O)O)cc1)c1O Chemical compound COc(cc(CCC(CC(CCc1ccccc1)=O)O)cc1)c1O JHJPDDBIHSFERA-UHFFFAOYSA-N 0.000 description 2
- RXVXMDZHFNUAGK-UHFFFAOYSA-N CC(C(C(C1O)OC(C(C2OC(C)=O)O)OCC2O)O)OC1OC(C)(CCC=C(C)C)C(C(C1)O)C(CC2)C1(C)C(C)(CC1)C2C(C)(CC2)C1C(C)(C)C2OC(C(C1O)O)OCC1O Chemical compound CC(C(C(C1O)OC(C(C2OC(C)=O)O)OCC2O)O)OC1OC(C)(CCC=C(C)C)C(C(C1)O)C(CC2)C1(C)C(C)(CC1)C2C(C)(CC2)C1C(C)(C)C2OC(C(C1O)O)OCC1O RXVXMDZHFNUAGK-UHFFFAOYSA-N 0.000 description 1
- UXMODMFPEVZYRG-JZKHGTLTSA-N CC(C(C(C1OC(/C(/C)=C/CC/C(/C)=C/CC/C(/C)=C/CCC(C)(C=C)OC(C(C2O)OC(C(C3O)O)OC(CO)C3O)OC(CO)C2O)=O)O)O)OC1OCC(C(C(C1O)O)O)OC1OC(C(C(C)OC1OC/C(/C)=C\CC/C(/C)=C/CC/C(/C)=C/CCC(C)(C=C)OC(C(C2O)OC(C(C3O)O)OC(CO)C3O)OC(CO)C2O)O)C1O Chemical compound CC(C(C(C1OC(/C(/C)=C/CC/C(/C)=C/CC/C(/C)=C/CCC(C)(C=C)OC(C(C2O)OC(C(C3O)O)OC(CO)C3O)OC(CO)C2O)=O)O)O)OC1OCC(C(C(C1O)O)O)OC1OC(C(C(C)OC1OC/C(/C)=C\CC/C(/C)=C/CC/C(/C)=C/CCC(C)(C=C)OC(C(C2O)OC(C(C3O)O)OC(CO)C3O)OC(CO)C2O)O)C1O UXMODMFPEVZYRG-JZKHGTLTSA-N 0.000 description 1
- JSGVRMXIAILPPO-UHFFFAOYSA-N CC(C(C1OC(C)=O)OC(C)=O)C(C)(CCC(C)(C=C)O)C2=C1C(C)(C)CCC2 Chemical compound CC(C(C1OC(C)=O)OC(C)=O)C(C)(CCC(C)(C=C)O)C2=C1C(C)(C)CCC2 JSGVRMXIAILPPO-UHFFFAOYSA-N 0.000 description 1
- MDZKJHQSJHYOHJ-DMHJTJTCSA-N CC(C)(CC1)CC2C3=CCC([C@@](C)(C[C@H]4O)C(CC5)C(C)(C)[C@H]4O)[C@]5(C)[C@]3(C)CC[C@@]12C(O)=O Chemical compound CC(C)(CC1)CC2C3=CCC([C@@](C)(C[C@H]4O)C(CC5)C(C)(C)[C@H]4O)[C@]5(C)[C@]3(C)CC[C@@]12C(O)=O MDZKJHQSJHYOHJ-DMHJTJTCSA-N 0.000 description 1
- LGQAXOACZFMCLH-YCRREMRBSA-N CC/C=C/C(CCc1ccccc1)=O Chemical compound CC/C=C/C(CCc1ccccc1)=O LGQAXOACZFMCLH-YCRREMRBSA-N 0.000 description 1
- PDJJPBVKFIHSHV-UHFFFAOYSA-N CCC(CC(CCc1ccccc1)=O)O Chemical compound CCC(CC(CCc1ccccc1)=O)O PDJJPBVKFIHSHV-UHFFFAOYSA-N 0.000 description 1
- NOHMOWQGVDSLNY-UXBLZVDNSA-N COc1cc(CC/C=C/C(CCc2ccccc2)=O)ccc1O Chemical compound COc1cc(CC/C=C/C(CCc2ccccc2)=O)ccc1O NOHMOWQGVDSLNY-UXBLZVDNSA-N 0.000 description 1
- ZWRRJEICIPUPHZ-MYODQAERSA-N C[C@@H](Cc(c(-c(c(C1)cc(OC)c2OC)c2OC)c2OC)cc3c2OCO3)[C@@]1(C)O Chemical compound C[C@@H](Cc(c(-c(c(C1)cc(OC)c2OC)c2OC)c2OC)cc3c2OCO3)[C@@]1(C)O ZWRRJEICIPUPHZ-MYODQAERSA-N 0.000 description 1
- WCGUUGGRBIKTOS-POPPTPIPSA-N C[C@H](CC1)[C@H](C)C2C3=CCC([C@@](C)(CC4)C(CC5)C(C)(C)[C@H]4O)[C@]5(C)[C@]3(C)CC[C@@]12C(O)=O Chemical compound C[C@H](CC1)[C@H](C)C2C3=CCC([C@@](C)(CC4)C(CC5)C(C)(C)[C@H]4O)[C@]5(C)[C@]3(C)CC[C@@]12C(O)=O WCGUUGGRBIKTOS-POPPTPIPSA-N 0.000 description 1
- IUWKHKOYFNICMB-RGEBSJJTSA-N C[C@](CO[C@H]1[C@H]([C@]2(C)[C@@H]3CC(OC)=O)O[C@H](C4)C2=C(C)[C@@H]4C2=C[U]=CC2)(C1[C@]3(C)[C@H](C1)OC(/C(/C)=C/C)=O)[C@@H]1OC(C)=O Chemical compound C[C@](CO[C@H]1[C@H]([C@]2(C)[C@@H]3CC(OC)=O)O[C@H](C4)C2=C(C)[C@@H]4C2=C[U]=CC2)(C1[C@]3(C)[C@H](C1)OC(/C(/C)=C/C)=O)[C@@H]1OC(C)=O IUWKHKOYFNICMB-RGEBSJJTSA-N 0.000 description 1
- ACVGWSKVRYFWRP-UHFFFAOYSA-N O=C1N(CCc2c3[nH]c4c2cccc4)C3=Nc2c1cccc2 Chemical compound O=C1N(CCc2c3[nH]c4c2cccc4)C3=Nc2c1cccc2 ACVGWSKVRYFWRP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L23/00—Soups; Sauces; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/40—Table salts; Dietetic salt substitutes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/40—Table salts; Dietetic salt substitutes
- A23L27/45—Salt substitutes completely devoid of sodium chloride
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/117—Flakes or other shapes of ready-to-eat type; Semi-finished or partly-finished products therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- This disclosure generally relates to, among other things, food products having a compound that modifies or enhances the taste of the food product, for example, the saltiness of the food product.
- Sodium chloride ordinary table salt
- sodium chloride is the prototypical compound for eliciting the perception of salty taste.
- attempts to reduce sodium consumption have led investigators to find suitable substitutes for sodium chloride or to reduce sodium chloride amounts, without sacrificing salty taste.
- Salts can elicit complex tastes, including mixtures of sweet, bitter, sour, umami, and salty perceptual components. It is believed that the cations of salts impart the perceptual taste component, while the anions, in addition to contributing to tastes of their own, modify the perception of the taste of the cations.
- sodium and lithium are believed to impart only salty tastes, while potassium and other alkaline earth cations produce both salty and bitter tastes.
- the chloride ion is considered to be the least inhibitory to the salty taste, while the citrate anion is more inhibitory.
- This disclosure describes, among other things, compounds that elicit or enhance the perception of salty taste, or another taste associated with consumption of sodium chloride or other salts, or that interact with a receptor or ion channel associated with the perception of salty taste or another complex taste associated with consumption of sodium chloride or other salts.
- the compounds are naturally derived taste modulating compounds used as ingredients in food products to elicit or enhance perception of salty taste.
- the food products contain lower amounts of sodium than normal.
- One or more embodiments of the compounds, compositions, food products or methods described herein provide one or more advantages over prior compounds, compositions, food products or methods.
- food products that include one or more taste modulating or salty taste modulating compounds described herein may have lower sodium content relative to food products that do not include such taste modulating or salty compounds while imparting a similar level of saltiness.
- FIG. 1 is a table that provides results of DAP score testing regarding the perception of saltiness of various combinations of compounds in sodium chloride solution.
- FIG. 2 is a table that provides results of DAP score testing regarding the perception of saltiness of various combinations of compounds in combination in broth solution.
- This disclosure describes, among other things, compounds that elicit or enhance the perception of salty taste or another taste associated with consumption of sodium chloride.
- the compounds are taste modulating compounds used as ingredients in food products to elicit or enhance perception of salty taste.
- the food products are food products that contain reduced amounts of sodium, while imparting a salty taste typically associated with higher amounts of sodium.
- a food product includes (i) a taste modulating or salty taste modulating compound, or derivatives thereof, or (ii) a composition that comprises a taste modulating or salty taste modulating compound, or derivatives thereof.
- the taste modulating, or salty taste modulating compound may be derived from a natural product, may be synthesized, or may be isolated or purified.
- a "food product” is a food in a form that does not exist in nature.
- a food product includes at least two edible ingredients that do not exist together in nature.
- a "food” is a nutritious substance that animals, including humans, pets and livestock, eat or drink.
- a "nutritious substance” is a macronutrient such as a fat, carbohydrate or protein, or a micronutrient such as an essential or non-essential vitamin or mineral.
- One or more taste modulating or salty taste modulating compounds described herein or derivatives thereof, alone or in combination, may be incorporated into a food product. The one or more compounds may elicit a perception of saltiness when the food product is consumed.
- the one or more compounds are included in a food product that contains a salt that imparts a salty taste.
- at least one of the one or more compounds is a taste modulating compound or salty taste modulating compound.
- a food product includes an ingredient, a salt that imparts a salty taste, and a taste modulating or salty taste modulating compound.
- the ingredient may be a nutritious ingredient; that is, an ingredient that is a nutritious substance.
- the taste modulating or salty taste modulating compound may be present in the food product in an amount sufficient to enhance the salty taste of the food product.
- the ingredient, the salt and the taste modulating or salty taste modulating compound are present in the food product in amounts or concentrations not found in naturally existing food products, such as bananas, peppers, avocadoes, wheat, or the like.
- At least one of the one or more compounds is a salty taste modulating compound and is present in the food product in an amount or concentration sufficient to elicit or enhance the perception of saltiness.
- the one or more salty taste modulating compounds are present in the food product in an amount or concentration sufficient to elicit or enhance the perception of salty taste such that less salt may be included in the food product to elicit a similar perception of saltiness as a substantially similar food product that does not include the one or more salty taste modulating compounds.
- the reduced salt food product elicits the same or a similar perception of saltiness as a substantially similar food product that does not include the one or more salty taste modulating compounds.
- the one or more taste modulating or salty taste modulating compounds are present in a food product in an amount or concentration sufficient to elicit or enhance the perception of salty taste such that the amount of sodium may be reduced by about 10 mg or more per serving relative to a substantially similar food product that does not have the one or more taste modulating or salty taste modulating compounds while having a similar salty taste.
- the one or more taste modulating or salty taste modulating compounds are present in a food product in an amount or concentration sufficient to elicit or enhance the perception of salty taste such that the amount of sodium in a serving of a food product may be reduced to about 150 mg or less, more particularly to about 100 mg or less, more particularly to about 75 mg or less, more particularly to about 25 mg or less, more particularly to about 10 mg or less.
- a typical serving size is 50 grams.
- cereals may have other serving sizes.
- the one or more taste modulating or salty taste modulating compounds are present in a food product in an amount or concentration sufficient to elicit or enhance the perception of salty taste such that the amount of sodium may be reduced by about 20 mg or more per serving relative to a substantially similar food product that does not have the one or more taste modulating or salty taste modulating compounds while having a similar salty taste.
- the one or more taste modulating or salty taste modulating compounds are present in a serving of a food product in an amount or concentration sufficient to elicit or enhance the perception of salty taste such that the amount of sodium may be reduced to about 800 mg or less, more particularly to about 500 mg or less, more particularly to about 300 mg or less, more particularly to about 100 mg or less, more particularly to about 20 mg or less.
- the amount of sodium may be reduced to about 800 mg or less, more particularly to about 500 mg or less, more particularly to about 300 mg or less, more particularly to about 100 mg or less, more particularly to about 20 mg or less.
- the one or more taste modulating or salty taste modulating compounds are present in a food product in an amount or concentration sufficient to elicit or enhance the perception of salty taste such that the amount of sodium may be reduced by about 100 mg or more per serving relative to a substantially similar food product that does not have the one or more taste modulating or salty taste modulating compounds while having a similar salty taste.
- the one or more taste modulating or salty taste modulating compounds are present in a serving of a food product in an amount or concentration sufficient to elicit or enhance the perception of salty taste such that the amount of sodium may be reduced to about 800 mg or less, more particularly to about 500 mg or less, more particularly to about 300 mg or less, more particularly to about 200 mg or less, more particularly to about 100 mg or less relative to a substantially similar food product that does not have the one or more taste modulating or salty taste modulating compounds while having a similar salty taste.
- a typical serving size is 250 grams.
- soups may have other serving sizes.
- a food product includes a combination of compounds such that the combination includes at least two structurally diverse taste modulating or salty taste modulating compounds.
- a food product or composition may include one or more compounds described herein, or derivatives thereof, in any suitable concentration.
- a compound described herein, or a derivate thereof, such as a taste modulating or salty taste modulating compound may be present in a food product at a concentration of about 0.01% by weight or greater, about 2% by weight or less, or from about 0.01 % by weight to about 2% by weight.
- concentration of the salt or salts in the food product may affect the desired concentration of a taste modulating or salty taste modulating compound. For example, if more salt is present, less taste modulating or salty taste modulating compound may be desired.
- any salt that imparts a salty taste may be present or incorporated into a food product that contains a bioactive, taste modulating, or salty taste modulating compound.
- the most commonly used salt for food applications is sodium chloride (typically referred to as common table salt).
- sodium salts that may be present of incorporated into a food product include sodium phosphates, mono sodium glutamate, sodium nitrite, sodium nitrate, sodium bicarbonate, sodium lactate, sodium citrate, and sodium stearoyl lactylate. Similar lithium, potassium, ammonium or other alkali earth salts may be present or included in addition or as an alternative to one or more sodium salts.
- a food product includes sodium chloride as a salt that imparts a salty taste.
- Sodium chloride may be present in the food product at any suitable amount or concentration.
- sodium chloride is present in the food product in an amount up to about 10.0 weight percent, more particularly, up to about 5.0 weight percent, even more particularly up to about 1.2 weight percent, or in the range of about 0.017 to about 1.2 weight percent, or about 0.1 to about 1, or about 0.4 to about 0.6 weight percent.
- a food product that includes one or more bioactive, taste modulating, or salty taste modulating compounds comprises no more than 0.04 weight percent, no more than 0.1 weight percent sodium, no more than 0.2 weight percent, no more than 0.25 weight percent sodium, no more than 0.3 weight percent, no more than 0.4 weight percent, no more than 0.5 weight percent sodium, no more than 0.75 weight percent sodium, no more than 1 weight percent sodium, no more than 5 weight percent sodium, or no more than 10 weight percent sodium.
- a desired weight percent of sodium may vary depending on the type of food product. For example, it may be desirable for a seasoning to have a higher weight percent sodium than a soup or a breakfast cereal.
- a food product that includes one or more taste modulating or salty taste modulating compounds comprises no more than 100 mg sodium per serving, no more than 250 mg sodium per serving, no more than 500 mg sodium per serving.
- One or more taste modulating or salty taste modulating compounds may be utilized in connection with virtually any food product for which it is desired to elicit or enhance the perception of a salty taste or other taste associated with consumption of a salt.
- the taste modulating or salty taste modulating compounds can find application for imparting saltiness to beverages or food dishes or as an ingredient in snack foods or other food products in which saltiness is desired.
- Examples of food products that may incorporate one or more taste modulating or salty taste modulating compound include a confectionary, a gum, a bakery product, an ice cream, a dairy product, a fruit snack, a chip or crisp, an extruded snack, a tortilla chip or corn chip, a popcorn, a pretzel, a nut, a snack bar, a meal replacement, a ready meal, a soup, a pasta, a canned food, a frozen processed food, a dried processed food, an instant noodle, a chilled processed food, an oil or fat, a sauce dressing or condiment, a dip, a pickled product, a seasoning, a baby food, a spread, a chip or a crisp such as chips or crisps comprising potato, corn, rice, vegetable (including raw, pickled, cooked and dried vegetables), a fruit, a grain, a soup, a seasoning, a baked product such as a ready-to-eat breakfast cereal, hot cereal or dough, an ice cream such as
- one or more bioactive, taste modulating, or salty taste modulating compounds are incorporated into a medicinal or pharmaceutical product, or the like.
- a food product is a processed food product.
- Food processing includes the transformation of raw ingredients into food or transforming forms of food into other forms of food.
- Food processing often includes using harvested crops or animal products to produce marketable products sold to consumers at stores, restaurants and the like.
- Processed food products include products for which additional processing by a consumer occurs after purchase but prior to consumption (e.g., heating, cooking, baking, or the like).
- Particularly suitable food products including soup, meal kits, grain products such as ready-to-eat cereals, snacks, bars and baked dough, and dairy products such as ice cream, yogurt and cheese.
- a bioactive, taste modulating, or salty taste modulating compound is used to reduce the amount of sodium salt that is typically included in soups, including (but not limited to) chicken or poultry broth, chicken- or poultry-based soups (such as chicken noodle soup), tomato-based soups, and the like.
- a taste modulating or salty taste modulating compound is used to reduce sodium salt in meal kits, such as kits that include ingredients to be combined with meat to prepare a meal.
- meal kits can include dried components (such as noodles, rice, dried potatoes, or the like) and seasoning packages.
- a taste modulating or salty taste modulating compound is used to reduce the sodium chloride that is typically added to a snack food to enhance its flavor.
- exemplary snack foods include potato chips, corn chips, pretzels, fruit-type snacks, and snack mixes including any mixes of any of these foods with other ingredients (such as cereals).
- a taste modulating or salty taste modulating compound is used to reduce the amount of sodium salt that is typically included in a ready-to-eat cereal or other grain-based food products, such as dough, baked goods, grain snacks, grain bars, or the like.
- a taste modulating or salty taste modulating compound is used to reduce the amount of sodium salt that is typically included in dairy-based food products, such as fresh or frozen dairy products, which may include yogurt, ice cream, or the like.
- a taste modulating or salty taste modulating compound is used to reduce the amount of sodium salt that is typically included in packaged meal food products, such as packaged meals that contain rice, potatoes, or vegetables, dry packaged meals, frozen packaged meals, or the like.
- grain includes grain and pseudograin.
- food grains include corn; sorghum; fonio; millet such as pearl millet, proso millet, finger millet, foxtail millet, Japanese millet, kodo millet and the like; Job's tears; wheat; rice; rye; barley; oat; triticale; wild rice; teff; amaranth; quinoa; buckwheat; and the like.
- a taste modulating or salty taste modulating compound can also be used in connection with soup, broth, sauce (such as basting sauce), various seasoning sauces, ketchup, dressings, and other like foods.
- a food product into which a taste modulating or salty taste modulating compound or composition is included has a water content of about 30% or more by weight.
- the food product may have a water content of about 35% or more, or about 40% or more by weight.
- Non-limiting examples of food products that typically have water contents of about 30%) or more by weight include soups, beverages, batters and dough.
- a food product into which a taste modulating or salty taste modulating compound or composition is included has a water content of about 50% or more by weight.
- the food product may have a water content of about 60% or more, or about 70% or more by weight.
- Non-limiting examples of food products that typically have water contents of about 50%) or more by weight include soups and beverages.
- a soup containing a taste modulating or salty taste modulating compound or composition may contain from about 50%) water by weight to about 90%> water by weight.
- a food product into which a taste modulating or salty taste modulating composition is included has a water content of about 20% or less by weight.
- the food product may be incorporated into dry food products that having low water contents.
- a taste modulating or salty taste modulating food product is included in a dried for as a seasoning.
- the seasoning comprises, consists essentially of, or consists of one or more taste modulating or salty taste modulating compounds, one or more carriers, and one or more salts.
- a taste modulating or salty taste modulating compound can be employed to elicit the perception of salty taste or enhance the perceived salt taste of any salts used in food or beverage products.
- the preferred salt taste to be elicited or enhanced by the salty compounds is that of sodium chloride.
- a taste modulating or salty taste modulating compound described herein can be used to elicit or enhance the perceived salt taste of known salty tasting compounds that may be used as salt substitutes.
- Such compounds include amino acids such as cationic amino acids and low molecular weight peptides such as dipeptides and tripeptides. Specific examples of these compounds include arginine hydrochloride, lysine hydrochloride, and lysine-ornithine hydrochloride. These compounds exhibit a salty taste but are typically useful only at low concentrations since they exhibit a bitter flavor at higher concentrations. Ordinarily, these salt- tasting compounds will be used in concentrations in the range of about 1 to about 40 mM, or about 10 to about 30 mM.
- sodium chloride content of a food or beverage product by first formulating a food or beverage with less sodium chloride than is necessary to achieve a desired salt taste and then adding to the food or beverage a taste modulating or salty taste modulating compound described herein in an amount sufficient to enhance the salt taste of the salted food or beverage to reach the desired taste.
- sodium chloride content may be further reduced by substituting a salt-tasting cationic amino acid, a low molecular eight dipeptide, or mixtures thereof, for at least a portion of the salt.
- a method includes setting a target salty taste of a food product, including an amount of a salt that imparts a salty taste in the food product, where the amount of the salt does not achieve the target level of salty taste, and including an amount of a salty taste enhancing compound (or more than one salty taste enhancing compounds) to achieve the desired salty taste.
- a method includes setting a target salty taste of a food product, including an amount of a salty-taste imparting sodium salt in the food product that does not achieve the target level of salty taste, including an amount of a non-sodium salt that imparts a salty taste and an amount of a salty taste enhancing compound (or more than one salty taste enhancing compounds) to achieve the desired salty taste.
- a taste modulating or salty taste modulating compound, or derivative thereof, described herein can be added to food products in dry or liquid form.
- a taste modulating or salty taste modulating compound that is in the liquid form can be prepared by simply dissolving or suspending the compound in an appropriate relative amount in an aqueous liquid.
- Useful aqueous liquids include water, alcohol-water mixtures, triacetin, propylene glycol, and triglycerides and other known organic solvents.
- taste modulating or salty taste modulating compounds that exist in a dry state can be prepared by either mixing or blending the compounds with other components in the dry state.
- the dry blending or mixing can be carried out in any conventional suitable apparatus.
- the taste modulating or salty taste modulating compounds described herein can be prepared into dry compositions by commonly used methods of granulation from mixtures of the several ingredients, preferably initially conveniently smaller than forty mesh.
- Such starting mixtures can be wetted in known manner, granulated, and their granulations dried as usual and screened to give a product approximately the typical size of common table salt, for example, by taking the fraction passing through the thirty mesh screen and retained on the forty mesh screen.
- Taste modulating or salty taste modulating compounds that exist in a dry composition state can be alternatively prepared by first forming a solution, emulsion or suspension of the compounds and other individual components, and then extruding or drying the solution or suspension.
- the preparation of the solution or suspension of the components can be carried out as described above in the context of preparing the liquid flavoring agents.
- the thus-prepared solution, emulsion or suspension can then be dried using any conventional suitable apparatus, such as a rotary drier, a drum drier, or a fluidized bed drier or spray drier.
- Taste modulating or salty taste modulating compounds described herein can be prepared by thoroughly mixing the compounds with other components in the indicated proportions until a suitably mixed (for example, homogeneous) product is attained.
- compositions or formulations containing the taste modulating or salty taste modulating compounds can then be combined with a food product.
- a composition that includes a salty taste modulating compound is perceived as imparting a quantity of saltiness equal to a substantially similar composition that does not include the salty taste modulating compound but that has a higher concentration of the salt.
- the composition that includes the salty taste modulating compound imparts a perception of saltiness equal to the substantially similar composition that does not have the salty taste modulating compound when the composition has less salt than the substantially similar composition (e.g., salt reduced by about 1% or more).
- the composition that includes the salty taste modulating compound may impart a perception of saltiness equal to the substantially similar composition that does not have the salty compound when the composition that includes the salty taste modulating compound has a salt concentration reduced by about 2% or more, about 5% or more, about 7% or more, about 8% or more, about 9% or more, about 10% or more, about 11% or more, about 15% or more, about 20% or more, about 30% or more, about 35% or more, about 40% or more, or about 50% or more, relative to the substantially similar composition.
- one or more salty taste modulating compounds may be present in a food product in an amount sufficient to reduce the amount of a salt, such as sodium chloride, by about 1% or more, about 2% or more, about 5% or more, about 7% or more, about 8% or more, about 10% or more, about 11% or more, about 12% or more, about 15% or more, about 20%) or more, about 22% or more, about 25% or more, about 30% or more, about 35% or more, about 40%) or more, about 45% or more, about 50% or more, about 55% or more, about 60% or more, about 65% or more, about 70% or more, about 75% or more, about 80% or more, about 85%) or more, about 90% or more, about 95% or more, or the like.
- the reduced salt food product elicits the same or similar perception of saltiness as a substantially similar food product that does not include the one or more salty taste modulating compounds.
- Perception of saltiness may be evaluated in any suitable manner.
- saltiness is determined by a trained analytical sensory panel.
- the trained sensory panel determines the saltiness of a composition having a salty taste modulating compound relative to a substantially similar composition having increased sodium chloride content.
- Sensory panelists may be trained in any suitable manner. Preferably, the panelists are trained to discern salty taste or other attributes without reference to liking or acceptability. The panelists are also preferably trained to accurately quantify salty taste or other attributes according to an intensity scale.
- General information that may be helpful in understanding beneficial training protocols can be found in, for example, Sensory Evaluation Techniques, 4 th Ed by Meilgaard M., Civille G.V. and Carr B.T (2007), CRC Press, pages 147-152.
- Prescreening, selection, and training of panelists may be occur as described in one or more standards, such as Hootman RC, Manual 13 MNL13 Manual on Descriptive Analysis Testing for Sensory Evaluation, ASTM (1992); STP758 Guidelines for the Selection and Training of Sensory Panel Members, ASTM (1981); and Munoz A.M and Civille, G.V., MLN13: The Spectrum Descriptive Analysis Method, ASTM (1992).
- panelists are trained according to the Spectrum Method (Munoz A.M and Civille, G.V., MLN13: The Spectrum Descriptive Analysis Method, ASTM 1992).
- a panel may contain three or more trained panelists, 5 or more trained panelists, 7 or more trained panelists, 10 or more trained panelists, or the like.
- a taste modulating or a salty taste modulating compound may be a compound that directly acts to elicit or enhance the perception of salty taste of a salt or may be a compound that is converted, when ingested, into a compound that directly acts to elicit enhance the perception of salty taste of the salt.
- the TrpML3 (transient receptor potential cation channel, mucolipin subfamily, member 3) channel, also known as Mucolipin-3 is a protein that, in humans, is encoded by the MCOLN3 gene.
- the TrpVl (transient receptor potential cation channel subfamily V member 1) channel also known as the capsaicin receptor and the vanilloid receptor 1 , is a protein that, in humans, is encoded by the TrpVl gene.
- the ENaC (epithelial sodium channel), also known as sodium channel non-neuronal 1 (SCNN1) or amiloride sensitive sodium channel (ASSC) is a membrane- bound ion-channel that is permeable for Li+-ions, protons and especially Na+-ions.
- Any compound that interacts with one or more of the TrpML3 channel, the TrpVl channel and the ENaC channel may be useful for modulating taste or saltiness of a food product into which the compound is incorporated.
- Schizandrol B Schisandra chinensis Five flavor berry
- peltatum hogapple Indian apple, mayflower, umbrella plant, wild mandrake, American mandrake
- peltatum hogapple Indian apple, mayflower, umbrella plant, wild mandrake, American mandrake
- Those compounds for which no CAS registry numbers are provided in Table 1, as well as those for which registry numbers are provided, may be isolated or purified in any suitable manner.
- the natural source of the compound, which is presented in Table 1 may be fractionated and the fractions subjected to chromatography, such as gas chromatography or HPLC, or other suitable separation process to isolate or purify the compound.
- chromatography such as gas chromatography or HPLC, or other suitable separation process to isolate or purify the compound.
- the selection of, for example, a chromatography column and parameters can be readily identified based on the chemical structure of the compound.
- obtained fractions, subtractions, or individual compounds may be tested for ability to activate a sodium channel, for example, expressed in cells in culture, cell membrane, or the like and employing an appropriate assay, such as an electrophysiological assay, a colorimetric assay, or the like.
- the compounds listed in Table 1 may be synthesized.
- companies that have access to the appropriate natural sources or the ability to test for sodium channel activity may be contracted to isolate the compounds.
- Companies that have access to natural products or natural product libraries that may include sources presented in Table 1 or that have expertise in development of assays for identification of compounds or fractions containing compounds capable of activating a sodium channel include Biotechnology Research And Information Network AG (Zwingengerg, Germany); AnalytiCon Discovery, GmbH (Potsdam, Germany); Albany Molecular Research, Inc.
- a compound may be in more than one category due to its structural similarity to compounds in more than one category. It will be understood that structural similarities of the various compounds other than those presented herein exist and that groupings into categories other than those presented herein are possible and contemplated.
- R 1 for the group A compounds is independently defined relative to R 1 for the group B compounds.
- discussion of substituents with regard to subgroups is independently defined.
- R 1 for the group Jl compounds is independently defined relative to R 1 for the group J2 compounds, unless otherwise stated.
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- R is H or Ci-Cio alkyl
- R 2 is H or C 1 -C 3 alkyl
- R 3 is H, C 1 -C 3 alkyl, or C R ;
- R 4 is H or C 1 -C 3 alkyl
- R 5 is H, OH, -OCH 3 , -OCH 2 CH 3 , -0-OCH 2 CH 2 CH ? , or ;
- R 5 is H. In embodiments, when Y is CHR 5 -CH 2 , R 5 is OH or -OCH 3 . In embodiments, R 6 is CH 3 . [0067] GROUP B COMPOUNDS [0068] Group B l Compounds
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- R 1 and R 2 are each independently OH or C 1 -C3 alkoxy or where R 1 and R 2 together with the carbons to which they are bound form a five-membered ring having two oxygen heteroatoms to form a compound having the following
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- R 1 and R 2 are each independently OH or C 1 -C3 alkoxy, and R 3 is selected from the group consisting of
- R 5 is H or C1-C3 alkyl, provided that if one of X or Y are CH then Z is also C s straight or
- R 1 and R 2 are OH.
- R 1 may be substituted at the 5 position
- R 2 may be substituted at the 3 position
- R 3 may be substituted at the 1 position.
- R 3 is Cio-C 2 o unsubstituted straight or branched chain alkenyl with one or more double bonds.
- R 3 may be C 12 -C 18 unsubstituted straight or branched chain alkenyl.
- R 3 may be C 13 -C 17 unsubstituted straight or branched chain alkenyl, such as Ci5 unsubstituted straight or branched chain alkenyl.
- R 3 has 1-5 double bonds.
- R 3 may have 1-4 double bonds, such as 1-3 double bonds.
- R is a straight chain alkenyl.
- R may be H 2 C
- R 1 is Ci-C 3 alkoxy, such as methoxy, and R 2 is OH.
- R 1 may be substituted at the 3 position
- R 2 may substituted at the 4 position
- R 3 may substituted at the 1 position.
- R 4 may be
- n is 2.
- Z is CH or CH 2
- X and Z are each independently CH or CH 2 , depending on whether Z is CH or CH 2 .
- X is CHOR 5 .
- R 5 may be H.
- Y is CO.
- X is CO.
- R may be any organic radical
- Y is CHOR 5 .
- R 5 may be C 1 -C3 alkyl.
- R 5 may be methyl.
- R 4 is Ci-Cs straight or branched chain alkyl.
- R 4 may be C4-C6 straight or branched chain alkyl, such as C5 straight or branched chain alkyl.
- R 4 is a straight chain alkyl.
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- a and B are each independently NCH 3 or C(O), with the proviso that one of A and B is NCH 3 and the other of A and B is C(O);
- Ri and R 2 are independently selected from H or Cg-Ci6 unsaturated alkyl, with the
- Ri and R 2 are independently selected from H or C 8 -Ci 6 unsaturated alkyl, wherein the Cs-Ci6 unsaturated alkyl contains 1 to 3 double bonds. In embodiments, Ri and R 2 are independently selected from H or Cg-Ci 6 unsaturated alkyl, wherein the Cg-Ci 6 unsaturated alkyl contains only 1 double bond.
- B is NCH 3 and R 2 is C 8 -Ci 6 unsaturated alkyl.
- Ri and R 2 are independently selected from H or Cn-C 15 unsaturated alkyl, such as Ci 3 unsaturated alkyl.
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- X is C or N
- R 1 is H, OH, Ci-C 3 alkoxy, or Ci-C 6 alkyl
- R 2 and R 3 are each independently selected from H; OH; Ci-C 3 alkoxy; straight or branched chain, saturated or unsaturated Ci-C 6 alkyl or alkenyl; or R 1 and R 2 together with the carbons to which they are bound form a part of a five or six membered ring structure;
- R 4 is H or Ci-C 3 alkyl
- R 5 is H, OH, C 1 -C 3 alkoxy or C 1 -C 3 alkyl
- R 5 is C 1 -C3 alkyl, such as methyl. In embodiments, when X is N, R 5 is C 1 -C3 alkyl, such as methyl. In embodiments, when X is N,
- R 5 is H or OH.
- Y is O.
- R 1 is H or methoxy.
- R 2 and R 3 together with the carbons to which they are bound form a part of a six membered ring structure.
- the six membered ring structure includes an oxygen or nitrogen heteroatom.
- the six membered ring structure contains one or more carbon atoms substituted with one or more Ci-C 6 alkyl, such as methyl.
- one carbon atom of the ring structure is substituted with two methyl groups.
- the ring structure is an unsubstituted six carbon aromatic ring structure.
- a compound according to Formula (C) has the following structure:
- a compound according to Formula (C) has the following structure
- R 2 and R 3 are each independently H, OH or C 1 -C 3 alkoxy;
- R 4 and R 5 are each independently H or C 1 -C 3 alkyl
- R 1 , R 2 and R 3 are H.
- R 1 , R 2 and R 3 are each independently OH or C 1 -C 3 alkoxy. In some embodiments, R 1 , R 2 and R 3 are the same.
- a and B together are part of an aromatic six-carbon membered unsubstituted ring structure.
- a compound according to Formula (C) has the following structure:
- R 1 , R 2 and R 3 are H.
- R 1 , R 2 and R 3 are each independently OH or C 1 -C 3 alkoxy.
- R 1 , R 2 and R 3 are the same.
- a and B together are part of an aromatic six-carbon membered unsubstituted ring structure.
- a compound according to Formula (C) has the following structure:
- X is N
- R 1 is H or C 1 -C 3 alkyl
- R 2 and R 3 are each independently selected from H and straight or branched chain
- R 4 is H or C 1 -C 3 alkyl
- R 5 is H or C 1 -C 3 alkyl
- Y is C-O-R 7 , where R 7 is H or C 1 -C 3 alkyl.
- each of R 1 , R 2 and R 3 are H.
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- R 7 is OCOCH3
- a and B are C, CH or CCH 3 , wherein when A and B are both C a double bond is formed between A and B;
- R 4 and R 5 are independently selected from OH, methyl,
- R 1 , R 6 and R 7 are as described above.
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- R 1 , R 2 and R 3 are independently selected from the group consisting of H and COCH 3 .
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- R is H or OH
- R are R each independently H or CH 3 ;
- R 1 and R 2 are each independently OH, C 1 -C3 alkyl or Ci-C 3 hydroxyl;
- R 3 and R 4 are each independently H, OH or Ci-C 3 hydroxyl
- R 5 is H or -OC(0)R 8 , where R 8 is Ci-C 8 straight or branched chain, saturated or
- W is CH
- Y is CH, X is CH or CH 2 , and Z is C or CR 9 , provided that Z is C when X is CH 2 , where R 9 is H or together with R 6 and the carbons to which they are bound and the intervening carbon of W form a five membered ring with an oxygen heteroatom;
- R 6 is Ci-C 3 hydroxyl, C(0)R 10 , (CH 2 )p'R 10 where p' is zero or l,or together with R 9 and the carbons to which they are bound and the intervening carbon of W form a five membered ring with an oxygen heteroatom, where R 10 is H, OH, or saccharidyl; and
- R 7 is H, OH, Ci-C 3 hydroxyl, or (CH 2 ) P R 44 , where p is zero or 1 and R 44 is saccharidyl. diments, R is saccharidyl and is
- R 11 is H or where d is zero or 1 ,
- R 1 7 is H, OH or CH 3 , and
- R 19 is H, OH or CH 3 .
- R 20 and R 21 are each independently H, C(0)R 43 where R 43 is C1-C15 straight or branched chain, saturated or unsaturated alkyl unsubstituted or substituted with hydroxyl,
- or g is zero or 1
- R , R and R are each independently H, OH or
- R is saccharidyl and is
- R 25 , R 26 , R 27 and R 28 are each independently H, OH, CH 3 , C1-C3 hydroxyl,
- R 31 , R 32 , R 33 and R 34 are each independently H, OH, CH 3 , C C 3 hydroxyl,
- R 37 , R 38 , R 39 and R 40 are each independently H, OH, CH 3 , Ci-C 3 hydroxyl, COOH, (CH 2 ) u OC(0)R 41 where u is zero, 1, 2 or 3 and R 41 is H or Ci-C 3 alkyl.
- Z is C. In embodiments, Z is CR 9 and wherein R 9 together with R 6 and the carbons to which they are bound and the intervening carbon of W for a five membered ring with an oxygen heteroatom.
- R 6 is C(0)R 10 .
- R 10 is H or OH.
- R 7 is OH.
- R 1 and R 2 are each independently Ci-C 3 alkly or Ci- C 3 hydroxyl.
- R 3 is H or OH.
- R 4 is H.
- R 5 is H.
- one or more of R 16 , if present, R 42 and R 43 are
- a compound according to Formula (F) has the following structure:
- R 1 and R 2 are each independently OH, Ci-C 3 alkyl or Ci-C 3 hydroxyl;
- R 3 and R 4 are each independently H, OH or C 1 -C 3 hydroxyl;
- R 5 is H
- W is CH
- Y is CH, X is CH or CH 2 , and Z is C or CR 9 , provided that Z is C when X is CH 2 , where R 9 is H or together with R 6 and the carbons to which they are bound and the intervening carbon of W form a five membered ring with an oxygen heteroatom;
- R 6 is C 1 -C 3 hydroxyl, C(0)R 10 , (CH 2 )p'R 10 where p' is zero or 1, or together with R 9 and the carbons to which they are bound and the intervening carbon of W form a five membered ring with an oxygen heteroatom, where R 10 is H or saccharidyl; and
- R 7 is H, OH, C 1 -C 3 hydroxyl, or (CH 2 ) p OR 44 , where p is zero or 1 and R 44 is saccharidyl. diments of a compound according to Formula F', R is saccharidyl and is
- R 14 is H, OH, CH 3 or Ci-C 3 hydroxyl
- R 15 is H, C(0)R 16 where R 16 is C1-C15 straight or branched chain, saturated or unsaturated alkyl unsubstituted or substituted with hydroxyl, where R 12 and R 13 are each independently H, C(0)R 41 where R 41 is C1-C15 straight or branched chain, saturated or unsaturated alkyl unsubstituted or substituted with hydroxyl, or
- R 1 7 is H, OH or CH 3 and
- R 19 is H, OH or CH 3 .
- R 20 and R 21 are each independently H, C(0)R 43 where R 43 is C1-C15 straight or branched chain, saturated or unsaturated alkyl unsubstituted or substituted with hydroxyl,
- or g is zero or 1
- R , R and R are each independently H, OH or
- R is saccharidyl and is
- R , R , R 1 ' and R Zii are each independently H, OH, CH , C1-C3 hydroxyl,
- R 31 , R 32 , R 33 and R 34 are each independently H, OH, CH 3 , C C 3 hydroxyl,
- R 37 , R 38 , R 39 and R 40 are each independently H, OH, CH 3 , Ci-C 3 hydroxyl, COOH, (CH 2 ) u OC(0)R 41 where u is zero, 1, 2 or 3 and R 41 is H or Ci-C 3 alkyl.
- Z is C.
- Z is CR 9 and wherein R 9 together with R 6 and the carbons to which they are bound and the intervening carbon of W for a five membered ring with an oxygen heteroatom.
- R 6 is C(0)R 10 .
- R 1 and R 2 are each independently Ci-C 3 alkly or Ci-C 3 hydroxyl.
- R 3 is H or OH.
- R 4 is H.
- R 16 if present, is
- a compound according to Formula (F) has the following structure:
- R 1 and R 2 are each independently OH, Ci-C 3 alkyl or Ci-C 3 hydroxyl;
- R 3 is H;
- R 4 is H, OH or C 1 -C3 hydroxyl;
- R 5 is H;
- W is CH;
- Y is CH, X is CH or CH 2 , and Z is C or CR 9 , provided that Z is C when X is CH 2 , where R 9 is H or together with R 6 and the carbons to which they are bound and the intervening carbon of W form a five membered ring with an oxygen heteroatom;
- R 6 is, together with R 9 and the carbons to which they are bound and the intervening carbon of W form a five membered ring with an oxygen heteroatom, or C(0)R 10
- R is H or where a and b are each independently zero
- R 11 is H, OH, or where d is zero or 1 ,
- R 15 is H, OH, CH 3 or Ci-C 3 hydroxyl
- R 15 is H, C(0)R 16 where R 16 is C 1 -C 15 straight or branched chain, saturated or unsaturated alkyl unsubstituted or substituted with hydroxyl
- R 12 and R 13 are each independently H
- C(0)R 41 where R 41 is C1-C15 straight or branched chain, saturated or unsaturated alkyl unsubstituted or substituted with hydroxyl, or
- R 17 is H, OH or CH 3 and
- R 18 is H, C(0)R 42 where R 42 is C 1 -C 15 straight or branched chain, saturated or unsaturated alkyl unsubstituted or substituted with hydroxyl, or
- R iy is H, OH or CH 3
- R 20 and R 21 are each independently H, C(0)R 43 where R 43 is C1-C15 straight or branched chain, saturated or unsaturated alkyl unsubstituted or substituted with hydroxyl,
- R , R and R are each independently H
- R is H, OH, C1-C3 hydroxyl, or (CH 2 ) P R , where p is zero or 1 and R is
- R , R , R / and R are each independently H, OH, CH 3 , Ci-C 3 hydroxyl,
- R 31 , R 32 , R 33 and R 34 are each independently H, OH, CH 3 , d-C 3 hydroxyl, COOH, (CH 2 ) q OC(0)R 35 where q is zero, 1, 2 or 3 and R 35 is H or Ci-C 3 alkyl, or (CH 2 ),OR 36 where t is zero or 1 and R 36 is
- R , R , R jy and R 4U are each independently H, OH, CH 3 , Ci-C 3 hydroxyl, COOH, (CH 2 ) u OC(0)R 41 where u is zero, 1, 2 or
- R 3 and R is H or Ci-C 3 alkyl.
- R 4 is H.
- R 1 is
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- R 1 is H or saccharidyl
- R 2 is H or OH
- R 3 and R 4 are independently selected from H or methyl or together form CH 2 ;
- R 5 is CH 2 or CH;
- R 6 is CH or C, provided that when R 5 is CH, R 6 is C;
- R 9 ' R 10 , and R 11 are independently H or methyl.
- R is saccharidyl and is
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- X is O or CH 2 ;
- R 1 and R 9 are independently selected from H, OH, C 1 -C 3 alkoxy, C 1 -C 3 alkyl, and
- R 2 and R 10 are independently selected from H, OH and C 1 -C 3 alkyl
- R 3 and R 4 are independently selected from H and C 1 -C 3 alkyl or together form CH 2 ;
- R 5 , R 6 and R 7 are independently selected from H and C 1 -C 3 alkyoxy
- R 8 is H, OH or C 1 -C 3 alkyoxy.
- R 5 , R 6 , R 7 and R 8 are independently C 1 -C 3 alkyoxy. In embodiments, R 5 , R 6 , R 7 and R 8 are independently C 1 -C 3 alkyoxy. In embodiments, R 5 , R 6 ,
- R 7 and R 8 are methoxy.
- R 3 and R 4 together form CH 2 .
- R 3 and R 4 are independently C 1 -C 3 alkyl.
- R 3 and R 4 are methyl.
- at least two of R 1 , R 2 , R 9 and R 10 are independently C 1 -C 3 alkyl.
- at least two of R 2 , R 9 and R 10 are methyl.
- X is CH 2 .
- X is O. In some embodiments where X is O, R 2 and R 10 are H. In some embodiments where X is 0,two or more or R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 10 are H. In some embodiments where X is 0,each of R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 10 are H. In some embodiments where X is O, R 8 is OH or C 1 -C 3 alkoxy. In some embodiments where X is O, R 1 and R 9 are independently selected from OH, C 1 -C 3 alkoxy, and (CH 2 ) n OH. In some embodiments where X is O, one of R 1 and R 9 is selected from OH and C 1 -C 3 alkoxy, and the other of R 1 and R 9 is (CH 2 ) n OH.
- a compound according to Formula (I) has the following structure:
- X is O
- R 1 and R 9 are independently selected from H, OH, C 1 -C 3 alkoxy, C 1 -C 3 alkyl, and
- R 2 and R 10 are independently selected from H, OH and C 1 -C 3 alkyl
- R 3 and R 4 are independently selected from H and C 1 -C 3 alkyl
- R 5 , R 6 and R 7 are H;
- R 8 is H, OH or C C 3 alkyoxy.
- R and R are H.
- each of R , R J , R ⁇ R 3 , R°, R', and R are H.
- R 1 and R 9 are independently selected from OH, C 1 -C 3 alkoxy, and (CH 2 ) n OH.
- one of R 1 and R 9 is selected from OH and C 1 -C 3 alkoxy, and the other of R 1 and R 9 is (CH 2 ) distractOH.
- a bioactive, taste modulating, or salty taste modulating is a compound having the following structure:
- R 1 and R 6 are each independently OH, C 1 -C 3 hydroxyl, C 1 -C 3 alkoxy or saccharidyl;
- R 2 , R 3 , R 7 and R 8 are each independently H, OH, C 1 -C 3 hydroxyl, C 1 -C 3 alkoxy;
- R 4 and R 5 are each independently H, OH, C 1 -C 3 alkyl, C 1 -C 3 alkoxy, or C 1 -C 3 hydroxyl;
- Y is CHCH and n is zero or 1 ;
- X is CHR 9 and m is zero or 1 , where R is where R 10 , R 11 and R 12 are each independently OH, C 1 -C 3 alkoxy, or C 1 -C 3
- R 1 , R 6 , or R 1 and R 6 are saccharidyl
- R 1 is OH.
- R 2 , R 3 , R 7 and R 8 are each independently H or C 1 -C 3 alkoxy. In embodiments, where one of wherein R 2 and R 3 is H and the other is C 1 -C 3 alkoxy, one of R 7 and R 8 is H and the other is C 1 -C 3 alkoxy.
- R , R , R and R are each H. In embodiments, R is present and is OH. In
- R 11 is present and is -C 3 alkoxy. In embodiments, R 1 is present and is OH. In
- R 9 is present and is
- R 11 , and R 12 are as defined above.
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are as defined above.
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are as defined above.
- R 1 and R 6 are each independently OH, C 1 -C 3 hydroxyl, C 1 -C 3 alkoxy or saccharidyl;
- R 2 , R 3 , R 7 and R 8 are each independently H, OH, C 1 -C 3 hydroxyl, C 1 -C 3 alkoxy;
- R 4 and R 5 are each independently H, OH, C 1 -C 3 alkoxy, or C 1 -C 3 hydroxyl;
- Y is CHCH and n is zero or 1 ;
- X is CHR 9 and m is zero or 1 , where R is where R 10 , R 11 and R 12 are each independently OH, C 1 -C 3 alkoxy, or C 1 -C 3
- R 1 , R 6 or R 1 and R 6 are saccharidyl and are .
- R 1 is OH.
- R 2 , R 3 , R 7 and R 8 are each independently H or C 1 -C 3 alkoxy.
- R 2 and R 3 is H and the other is C 1 -C 3 alkoxy, and one of R 7 and R 8 is H and the other is C 1 -C 3 alkoxy.
- R 2 , R 3 , R 7 and R 8 are each H.
- R 10 is present and is OH.
- R 11 is present and is C 1 -C 3 alkoxy.
- R 12 is present and is OH.
- R 9 is present and is
- R 10 , R 11 , and R 12 are as defined above.
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- R 1 is H, OH, or saccharidyl
- R 2 and R 3 are each independently H or C 1 -C3 alkyl; R 4 and R 5 are each independently H, , or CHC(R 10 )R n , where
- R 10 and R i 1 l 1 l are each independently -C5 alkyl unsubstituted or
- R 12 is H, OH, or saccharidyl
- B is C or CH, provided that if B is C then A is CR
- R 1 is saccharidyl and is
- R 6 , R 7 , R 8 , and R 9 are each independently H, OH, CH 3 , or CH 2 OH.
- R is saccharidyl and is
- R 13 , R 14 , R 15 , and R 16 are each independently H, OH, CH 3 ,
- R is CHC(CH 3 ) 2
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- R 1 , R 3 , R 4 , R 5 and R 6 are each independently H, OH, C 1 -C3 hydroxyl or C 1 -C3 alkoxy; and R 2 is H, C 1 -C 3 alkyl, or where R 7 , R 8 and R 9 are each independently OH, C 1 -C 3 hydroxyl or C 1 -C 3 alkoxy.
- R 2 is C 1 -C 3 alkyl, such as methyl.
- R 5 is OH or C 1 -C 3 hydroxyl.
- R 3 is H.
- R 4 is C 1 -C 3 alkoxy, such as methoxy.
- R 6 is C 1 -C 3 alkyl, such as methyl or propyl.
- R 1 is H.
- R 1 is C 1 -C 3 hydroxyl, such as C 2 hydroxyl.
- R 2 is
- R 7 , R 8 and R 9 are each independently OH or C 1 -C 3 alkoxy. In embodiments, R 7 is OH and R 8 and R 9 are each independently C 1 -C 3 alkoxy, such as methoxy.
- R 3 is OH, C 1 -C 3 hydroxyl, or C 1 -C 3 alkoxy.
- R 5 is H.
- R 6 is C 1 -C 3 alkoxy, such as methoxy.
- R 1 is C 1 -C 3 alkoxy, such as methoxy.
- R 4 is H.
- R 1 is OH, C 1 -C 3 hydroxyl or C 1 -C 3
- R is H, C 1 -C 3 alkyl, or , where R 7 , R 8 and R 9 are each independently OH, C 1 -C 3 hydroxyl or C 1 -C 3 alkoxy; and (iii) R 3 , R 4 , R 5 and R 6 are each independently H, OH, C 1 -C 3 hydroxyl or C 1 -C 3 alkoxy.
- R 2 is C 1 -C 3 alkyl, such as methyl.
- R 5 is OH or C 1 -C 3 hydroxyl.
- R 3 is H.
- R 4 is C 1 -C 3 alkoxy, such as methoxy.
- R 6 is C 1 -C 3 alkyl, such as butyl.
- R 1 is C 1 -C 3 hydroxyl.
- R 2 is H, C 1 -C 3 alkyl, or , where R 7 , R 8 and R 9 are each independently OH, C 1 -C 3 hydroxyl or C 1 -C 3
- R , R and R may each independently be OH or C 1 -C 3 alkoxy.
- R 7 may be OH and R 8 and R 9 may each independently be C 1 -C 3 alkoxy, such as
- R 3 is OH, C 1 -C 3 hydroxyl, C 1 -C 3 alkoxy. In some , R is H. In some
- R is C 1 -C 3 alkoxy, such as methoxy.
- R 2 is R 1 is C 1 -C3 alkoxy, such as methoxy.
- a compound according to Formula L is a compound having the following structure:
- R 1 , R 3 , R 4 , R 5 and R 6 are each independently H, OH, C 1 -C 3 hydroxyl or C 1 -C 3 alkoxy;
- R 7 , R 8 and R 9 are each independently OH, C 1 -C 3 hydroxyl or C 1 -C 3 alkoxy.
- R 7 , R 8 and R 9 are each independently
- R 7 is OH and R 8 and R 9 are each independently C 1 -C 3 alkoxy, such as methoxy.
- R 3 is OH, C 1 -C 3 hydroxyl, or C 1 -C 3 alkoxy.
- R 5 is H.
- R 6 is C 1 -C 3 alkoxy, such as methoxy.
- R 1 is C 1 -C 3 alkoxy, such as methoxy.
- R 4 is H.
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- X is CH or CH 2 ;
- Y is CH or C, with the caveat that if Y is C, then X is CH;
- R 5 is OH, C(0)OH, or OC(0)R 6 , where R 6 is a C r
- R 2 and R 3 are independently H, or substituted with hydroxyl or unsubstituted saturated or unsaturated branched or straight Ci-C 6 alkoxy;
- R 4 is H, or a saturated or unsaturated branched or straight Ci-C 6 alkyl.
- R 2 or R 3 is H. In embodiments, both R 2 and R 3 are H. In embodiments, at least one of R 2 and R 3 is a substituted saturated or unsaturated branched or straight Ci-C 6 alkoxy substituted with at least one hydroxyl group. In embodiments, both R 2 and R 3 are independently selected from a substituted saturated or unsaturated branched or straight Ci- C 6 alkoxy substituted with at least one hydroxyl group. For example, at least one of R 2 and R 3 can be methoxy. In embodiments, at least one of R 2 and R 3 is unsaturated. In embodiments, at least one of R 2 and R 3 is branched. In embodiments, R 2 is a straight unsubstituted saturated Ci- C 3 alkoxy; and R 3 is a branched unsubstituted, unsaturated C3-C6 alkoxy.
- R 4 is saturated or unsaturated branched or straight Ci-C 6 alkyl.
- R 4 can be C 5 alkyl. In embodiments, R 4 is unsaturated. In embodiments, R 4 is CH(CH 3 ) 2 CHCH 2 .
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- X is selected from NH, O, C(O), CR 5 or CR 5 R 6 , where R 5 and R 6 are independently
- Y, and Z are independently selected from O, CR 5 , CR 5 R 6 , where R 5 and R 6 are
- R 1 is H, C 1 -C 3 alkoxy, C(0)R 7 , where R 7 is a Ci to C 6 straight or branched alkyl, or
- R 8 , R 9 and R 10 are independently selected from: alkoxy, or C 3 to Cg alkyl;
- R is H, OH, where R 11 is H, OH, or Ci to C 3 hydroxyl;
- R 3 is H, C 1 -C 3 alkoxy, or together with R 4 form a six membered ring having an oxygen heteroatom to form a compound having a structure of:
- R 4 is H, Ci to C 3 alkoxy, or together with R 3 forms the structure above.
- X is CR 5 R 6 . In embodiments, X is C(OH)(CH 2 CH 2 CH 2 CH 3 ). In embodiments,
- X is O. In embodiments, X is CH 2 .
- Y is O.
- Y is CR 5 R 6 , where R 5 and R 6 are H and a branched Ci to C 6 hydroxyl, such as C(CH 3 )(CH 3 )OH.
- Y is CH.
- Z is C(O). In embodiments, Z is CH 2 . In embodiments, Z is O.
- R 1 is . In embodiments,
- Rl is a Ci-C 3 alkoxy.
- R 1 is C(0)R 7 , where R 7 is a Ci to C 6 straight or branched alkyl.
- R is a branched C 3 alkyl.
- R 2 is OH.
- R 2 is
- R 3 together with R 4 form a six membered ring having an oxygen heteroatom to form a compound having the structure:
- R 3 is H. In embodiments, R 3 is a C 1 -C3 alkoxy. In embodiments, R 4 is H.
- X is NH
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- Y is independently selected from CR 5 , CR 5 R 6 , where R 5 and R 6 are independently
- R 1 is H, -C 3 alkoxy, C(0)R 7 , where R 7 is a Ci to C 6 straight or branched alkyl, or
- R is H where R 11 is H, OH, or Ci to C 3 hydroxyl
- R 3 is H, C 1 -C 3 alkoxy, or together with R 4 for mm aa ssiixx mmeemmbbeenred ring having an oxygen heteroatom to form a compound having a structure of:
- R 4 is H, Ci to C3 alkoxy, or together with R 3 forms the structure above.
- R 1 is Ci to C3 alkoxy. In embodiments, R 1 is H. In embodiments, R 2 is H. In embodiments, R 3 is H. In embodiments, R 4 is H.
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- R 1 is H or a saturated or unsaturated Ci to C 6 alkyl
- R is H or a Ci to C 3 alkoxy
- R J is H or where R 4 , R 5 ,
- R 6 , R 7 , and R 8 are independently selected from: H, OH, Ci to C3 hydroxyl, Ci to C 3 alkoxy, and Ci to C 3 alkyl;
- X is NH or O.
- R 1 is H.
- R 2 is methoxy.
- R 2 is H.
- R 3 is H.
- R 3 is
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- A is a. CR 9 where R 9 is H, saturated or unsaturated Ci to C 6 alkyl, Ci to C 3 hydroxyl or CHR 10 , where R 10 is Ci to C 6 alkyl; b. CCR M R b5 R , where R , R , and R bb are independently selected from: Ci to C saturated or unsaturated, branched or straight chain alkyl, or (CH 2 ) a R U where a is zero or 1 and
- R 11 is H, OH, or saccharidyl, c. CR , where R is saturated or unsaturated, substituted with an oxygen or unsubstituted five membered ring including at least one oxygen heteroatom,
- R and R are H, OH, Ci to C 3 alkyl, Ci to C 3 alkoxy, or Ci to C 3 hydroxyl;
- B is CH 2 , or CH, with the caveat that if B is CH then D is C;
- D, E, F, and G are independently selected from: C, CR , where R is H, OH, Ci to C 3 alkyl, or Ci to C 3 hydroxyl, with the caveat that if D is C, then B is CH; if E is C, then G is C; and if F is C, then u is zero;
- Z is selected from CR R , where R and R are independently selected from H, OH, Ci to C 3 hydroxyl, or Ci to C 3 alkyl, with the caveat that is v is zero then k is also zero;
- K is CR 5 U R 6 , where u is zero or 1 and R 5 and R 6 are independently selected from H, OH, Ci to C 3 alkyl, Ci to C 3 hydroxyl, Ci to C 3 alkoxy, with the caveat that if u is zero than F is C;
- L is CR 34 k R 35 where k is zero or 1 and R 34 and R 35 are independently selected from H, OH, Ci to C 3 alkyl, Ci to C 3 hydroxyl, with the caveat that if v is zero then k is zero;
- M is C(O), COC(0)R 36 where R 36 is Ci to C 3 alkyl, CH(OH), CH(CH 2 ) j R 37 where j is zero, 1, or 2 and R 37 is H, OH, or saccharidyl;
- Q is C(O), or CR 61 R 62 , where R 61 and R 62 are independently selected from H, OH, Ci to C 3 alkyl, Ci to C 3 hydroxyl or along with A form a five membered ring containing an oxygen heteroatom, or structure Q1A;
- R 1 , R 3 , and R 7 are independently selected from H, OH or Ci to C 3 alkyl;
- R 2 is selected from H, O, OH or Ci to C 3 alkyl
- R 4 and R 8 are independently selected from H, C(O), OH, Ci to C 3 alkyl, C(0)R 63 where R 63 is H or Ci to C 3 alkyl, or OC(0)R 64 where R 64 is Ci to C 3 alkyl, or H.
- A is CR 23 , wherein R 23 is saturated or unsaturated, substituted with an oxygen or unsubstituted five membered ring including at least one oxygen heteroatom. [00189] In embodiments, R 23 is
- A is CR 9 , where R 9 is H, saturated or unsaturated Ci to C 6 alkyl, Ci to C 3 hydroxyl or CHR 10 , where R 10 is Ci to C 6 alkyl.
- R 9 is CHR 10 .
- R 10 is CH 3 .
- A along with Q and the atoms attached thereto form a ring structure of formula
- R and R are H, OH, Ci to C 3 alkyl, Ci to C 3 alkoxy, or Ci to C 3 hydroxyl.
- R 27 and R 28 are each CH 3 .
- A is CCR 64 R 65 R 66 , where R 64 , R 65 , and R 66 are independently selected from: d to Cio saturated or unsaturated, branched or straight chain alkyl, or (CH 2 ) a R n where a is zero or 1 and R 11 is H, OH, or where a' is zero or 1, R , R , R , and R are each independently H, OH, CH 3 , Ci-C 3 hydroxyl, COOH, (CH 2 ) b OC(0)R 16 where b is zero, 1, 2 or 3 and R 16 is H or Ci-C 3 alkyl, or (CH 2 )dO(CH 2 )d'R 17 , where d and d' are independently zero (0) or 1 and R 17 is H or
- R 18 , R 19 , R 20 and R 21 are each independently H, OH, CH 3 , Ci-C 3 hydroxyl, COOH, (CH 2 ) e OC(0)R 22 where e is zero, 1, 2 or 3 and R 22 is H or Ci-C 3 alkyl.
- R 64 is CH 3
- R 65 is a C 3 to Cg unsaturated, branched or chain alkyl
- R 66 is (CH 2 ) a O(CH 2 ) a' R u where a and a' are both zero and R 11 is H or
- R 12 , R 13 , and R 15 are each independently H, OH, CH 3 , C 1 -C3 hydroxyl, and
- R 18 , R 19 , R 20 and R 21 are each independently H, OH, CH 3 , C C 3 hydroxyl, COOH, OC(0)R 22 where R 22 is H or Ci-C 3 alkyl.
- R 12 , R 13 , and R 15 are each independently OH or CH 3 .
- R 18 , R 19 , and R 21 are each independently OH or H and R 20 is OC(0)CH 3 .
- A is CR , where R is where R and are independently selected from H, OH, or Ci to C 6 branched or straight hydroxyl.
- R b is OH and R" is C(CH 3 ) 2 OH
- Q is CR 61 R 62 , where R 61 and R 62 are independently selected from H, OH, Ci to
- Q is CH 2 . In embodiments, Q is CHOH. In embodiments, Q is C(O).
- B is CH 2 . In embodiments, B is CH and D is C.
- D is CR 29 , where R 29 is H, OH, Ci to C 3 alkyl, or Ci to C 3 hydroxyl.
- R is OH. In embodiments, R is H. In embodiments, R is CH 3 .
- E is CR , where R 9 is H, OH, Ci to C 3 alkyl, or Ci to C 3 hydroxyl.
- R 29 is H. In embodiments, R 29 is CH 3 . In embodiments, E is C and G is C.
- G is CH.
- F is CH.
- K is CH and F is C.
- K is CR 5 U R 6 , where u is 1 and R 5 and R 6 are independently selected from Ci to
- R 5 and R 6 are both CH 3 . In embodiments, R 5 and R 6 are both H.
- both J and L are CH.
- J is CH 2 .
- J is
- L is CH 2 .
- M is CHOH. In embodiments, M is CH(CH 2 ) j R 37 where j is zero, 1, or 2 and
- R 37 is H or
- R 38 , R 39 , R 40 , and R 41 are each independently selected from H, OH, CH 3 , Ci-C 3 hydroxyl, Ci - C 3 alkoxy, COOH, (CH 2 ) m OC(0)R 42 where m is zero, 1, 2 or 3 and R is H or C 1 -C3 alkyl, or (CH 2 ) deliberately0(CH 2 ) administrat ⁇ R , where n and n' are independently zero or 1 and R 43 is H or
- R , R , R 4b and R 4 / are each independently H, OH, CH 3 , Ci-C 3 hydroxyl, COOH, (CH 2 ) p OC(0)R 48 where p is zero, 1, 2 or 3 and R 48 is H or Ci-C 3 alkyl, or (CH 2 ) q O(CH 2 ) q >R 49 where q and q' are independently zero or 1 and R 49 is H or
- R 50 , R 51 , R 52 and R 53 are each independently H, OH, CH 3 , Ci-C 3 hydroxyl, COOH, (CH 2 ) r OC(0)R 54 where r is zero, 1, 2 or 3 and R 54 is H or Ci-C 3 alkyl, or
- R , R , R 5S and R 59 are each independently H, OH, CH 3 , C 1 -C3 hydroxyl, COOH, (CH 2 ),OC(0)R 60 where t is zero, 1, 2 or 3 and R 60 is H or Ci-C 3 alkyl.
- j and j ' are both zero and R 38 is CH ; R 39 is OH; R 40 is OCH 3 ; and R 41 is H.
- j and j ' are both zero and R 39 is (CH 2 ) n O(CH 2 ) n R 43 , where n and n' are independently zero or 1 and R 43 is H or
- R 44 , R 45 , R 46 and R 4 / are each independently H, OH, CH 3 , Ci-C 3 hydroxyl,
- R 44 is CH 2 OH; and R R 4( ⁇ and R 4 / are all OH.
- M is CH(CH 2 ) j R 3 / where R 3 / is H, OH, or where j ' is zero or 1 , R and R are each independently selected from H, OH, CH 3 , Ci-C 3 hydroxyl, Ci - C 3 alkoxy, COOH, (CH 2 ) m OC(0)R 42 where m is zero, 1, 2 or 3 and R 42 is H or C C 3 alkyl; where R 39 is OR 43 , where R 43 is H or
- R , R and R are each independently H, OH, CH 3 , Ci-C 3 hydroxyl, COOH, (CH 2 ) p OC(0)R 48 where p is zero, 1, 2 or 3 and R 48 is H or Ci-C 3 alkyl; and R 46 is (CH 2 ) q O(CH 2 ) q >R 49 where q and q' are independently zero or 1 and R 49 is H or
- R 50 , R 51 and R 53 are each independently H, OH, CH 3 ,
- R , R , R and R 5y are each independently H, OH, CH 3 or Ci-C 3 hydroxyl
- R 4U is OR , and R is H or
- R 44 , R 45 , R 46 and R 47 are each independently OH, or C1-C3 hydroxyl.
- M is CO
- R 1 is H or C 1 -C3 alkyl. In embodiments R 1 is CH 3 .
- R is H, OH, O, or C 1 -C 3 alkyl.
- R is H or C 1 -C 3 alkyl.
- R 4 is CH 3 . In embodiments, R 4 is CHO.
- R and R are both H.
- R is OCOCH 3
- F is CR , where R /y is H, OH, C C 3 alkyl, or C C 3 hydroxyl.
- K is CR 5 R 6 .
- M is C(O), COC(0)R 36 , where R 36 is d-C 3 alkyl, CH(CH 2 )jR 37 where j is zero or 1.
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure: (Q1B)
- R and R are H, OH, Ci to C 3 alkyl, Ci to C 3 alkoxy, or Ci to C 3 hydroxyl;
- D, E, F, and G are independently selected from: CR 29 , where R 29 is H, OH, Ci to C 3 alkyl, or Ci to C 3 hydroxyl;
- K is CR 5 R 6 , where R 5 and R 6 are independently selected from H, or Ci to C 3 alkyl;
- M is CH(CH 2 ) j R 37 where j is zero, 1, or 2 and R 37 is H, OH, or saccharidyl; Q is CHOH, or along with A form a five membered ring containing an oxygen
- heteroatom or structure II
- R 1 , R 2 R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are independently selected from H, OH, O, or Ci to C 3 alkyl.
- A along with Q and the atoms attached thereto form a ring structure of formula
- R and R are H, OH, Ci to C 3 alkyl, Ci to C 3 alkoxy, or Ci to C 3 hydroxyl.
- R 27 and R 28 are each CH 3 .
- A is CCR M R W R , where R , R , and R* are independently selected from: Ci to Cio saturated or unsaturated, branched or straight chain alkyl, or (CH 2 ) a O(CH 2 ) a' R n where a and a' are independently zero or 1 and R 11 is saccharidyl and is:
- R , R , R , and R are each independently H, OH, CH 3 , Ci-C 3 hydroxyl, COOH, (CH 2 ) b OC(0)R 16 where b is zero, 1 , 2 or 3 and R 16 is H or Ci-C 3 alkyl, or (CH 2 ) d O(CH 2 ) d' R 17 , where d and d' are independently zero (0) or 1 and R 17 is H or
- R 18 , R 19 , R 20 and R 21 are each independently H, OH, CH 3 , C C 3 hydroxyl, COOH, (CH 2 ) e OC(0)R 22 where e is zero, 1, 2 or 3 and R 22 is H or Ci-C 3 alkyl.
- R 64 is CH 3
- R 65 is a C 3 to C 8 unsaturated, branched or chain alkyl
- R 66 is (CH 2 )aO(CH 2 )a'R 11 where a and a' are both zero and R 11 is saccharidyl and is:
- R , R , and R are each independently H, OH, CH 3 , Ci-C 3 hydroxyl, and R is (CH 2 ) d O(CH 2 ) d' R 17 , where d and d' are independently zero (0) or 1 and R 17 is H or
- R 18 , R 19 , R 20 and R 21 are each independently H, OH, CH 3 , Ci-C 3 hydroxyl, COOH, OC(0)R 22 where R 22 is H or Ci-C 3 alkyl.
- R 12 , R 13 , and R 15 are each independently OH or CH 3 .
- R 18 , R 19 , and R 21 are each independently OH or H and R 20 is OC(0)CH 3 .
- M is CH(CH 2 ) j R 37 where j is zero, 1, or 2 and R 37 is saccharidyl and is:
- R 38 , R 39 , R 40 , and R 41 are each independently selected from H, OH, CH 3 , Ci-C 3 hydroxyl, Ci - C 3 alkoxy, COOH, (CH 2 ) m OC(0)R 42 where m is zero, 1, 2 or 3 and R 42 is H or Ci-C 3 alkyl, or (CH 2 ) n O(CH 2 ) n' R 43 , where n and n' are independently zero (0) or 1 and R 43 is H or
- R , R , R 4b and R 4 / are each independently H, OH, CH 3 , Ci-C 3 hydroxyl, COOH, (CH 2 ) p OC(0)R 48 where p is zero, 1, 2 or 3 and R 48 is H or C C 3 alkyl, or (CH 2 ) q O(CH 2 ) q >R 49 where q and q' are independently zero or 1 and R 49 is H or where R 50 , R 51 , R 52 and R 53 are each independently H, OH, CH 3 , Ci-C 3 hydroxyl, COOH, (CH 2 ) r OC(0)R 54 where r is zero, 1, 2 or 3 and R 54 is H or Ci-C 3 alkyl, or (CH 2 ) s O(CH 2 ) s R 55 where s and s' are independently zero or 1 and R 55 is H or
- R , R , R and R 3y are each independently H, OH, CH 3 , Ci-C 3 hydroxyl, COOH, (CH 2 ) t OC(0)R 60 where t is zero, 1, 2 or 3 and R 60 is H or C C 3 alkyl.
- j and j' are both zero and R 38 is CH 3 ; R 39 is OH; R 40 is OCH 3 ; and R 41 is H.
- j and j' are both zero and R 39 is (CH 2 ) n O(CH 2 ) n >R 43 , where n and n' are independently zero or 1 and R 43 is saccharidyl and is:
- R 44 , R 45 , R 4b and R are each independently H, OH, CH 3 , d-C 3 hydroxyl
- R 44 is CH 2 OH; and R 4 ⁇ R 4b , and R 4 / are all OH.
- D is CR , where R is Ci to C 3 alkyl.
- E is CR , where R is Ci to C 3 alkyl.
- G is CH.
- F is CH.
- K is CH and F is C.
- K is CR U R , where u is 1 and R and R are independently selected from Ci to
- R 5 and R 6 are both CH 3 .
- R 2 , R 4 , R 8 , and R 9 are all H.
- R 1 is C 1 -C3 alkyl. In embodiments, R 1 is H.
- R is O. In embodiments, R is H.
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure: (Q2) where A is C or CR 4 , where R 4 is H, OH, Ci to C 3 alkyl, with the caveat that if A is C, then B is CR 6 ;
- B is CR 5 a R 6 , where a is zero (0) or 1, and R 5 and R 6 are independently selected from H, OH, Ci to C 3 alkyl, with the caveat that if A is C, then B is CR 6 ;
- X is H, or along with Y and the atoms attached thereto form a ring structure having formula (Q2A) below,
- R 9 and R 10 are independently selected from O and CH 2 ;
- Z is H or along with Y and the atoms attached thereto form a ring structure having formula (Q2B) below,
- R and R are independently selected from O and CH 2 ;
- R 2 and R 3 are independently selected from H, CH 2 , Ci to C 3 alkyl.
- A is CH 3 .
- R 1 is CH 2 .
- R 2 is H.
- R 3 is H.
- A is CR 4 , where R 4 is Ci to C 3 alkyl.
- B is CH 2 .
- R 9 is O and R 10 is CH 2 .
- Y and Z along with the atoms attached thereto form a ring structure having formula (Q2B) below, where R 13 and R 14 are independently selected from O and CH 2 .
- R 3 is CH 3 .
- R 1 is H.
- R 2 is CH 2 .
- R 2 is CH 3 .
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- A is C or CR 4 , where R 4 is H, OH, Ci to C 3 alkyl, with the caveat that if A is C, then B is CR 6 ;
- B is CR 5 a R 6 , where a is zero or 1, and R 5 and R 6 are independently selected from H, OH, Ci to C 3 alkyl;
- Z is H or CR U R 12 where R 11 and R 12 are independently selected from H, OH, Ci to C 3 alkyl; R 2 and R 3 are independently selected from H, CH 2 , or a saturated or unsaturated Ci to C 6 alkyl; and
- R 9 and R 10 are independently selected from O or CH 2 .
- A is CCH 3 .
- B is CH 2 .
- Z is H.
- R 1 is CH 2 .
- R 2 is H.
- R3 is H.
- R 9 is O.
- R 10 is CH 2 .
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- R 1 is OH or saccharidyl
- R 2 and R 3 are independently H, OH, and COOH;
- R 4 is C 3 -C14 saturated or unsaturated alkyl optionally substituted with one or more hydroxyls.
- R 1 is OH.
- R 2 is H.
- R 2 is OH.
- R 3 is H.
- R 3 is COOH.
- R 4 is C 9 to C 13 unsaturated alkyl.
- R 4 is C 9 to C 13 unsaturated alkyl with at least one hydroxyl.
- R 4 is C 10 to C 12 alkyl with at least two double bonds, such as Cn with at least two double bonds.
- R 4 is Cn with three double bonds.
- R 4 is Cii with three double bonds and one hydroxyl.
- R 4 is C 3 to C 7 with at least one double bond.
- Rl is a compound where R 2 and R 3 are independently H, OH, and COOH; and R 4 is C3-C 10 saturated or unsaturated alkyl optionally substituted with one or more hydroxyls.
- R 2 is OH.
- R 3 is COOH.
- R 4 is C 3 to C 7 with at least one double bond.
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- A is (CH 2 ) x , where x is 0 or 1 ;
- R 5 is saccharidyl;
- R 2 and R 3 are independently H, OH, and COOH;
- R 4 is C 8 -Ci 6 saturated or unsaturated alkyl optionally substituted with one or more hydroxyls.
- A, D, E and G are independently (CH 2 ) X , where x is 0 or 1 ; R 1 is H or saccharidyl;
- R 2 and R 3 are independently H, OH, and COOH;
- R 4 is C 8 -Ci 6 saturated or unsaturated alkyl optionally substituted with one or more hydroxyls.
- R 1 is H.
- R 2 is H.
- R 3 is H.
- R 4 is Cg to CM unsaturated alkyl optionally substituted with one or more hydroxyls, such as Cio to Ci 3 unsaturated alkyl optionally substituted with one or more hydroxyls. In embodiments, R 4 is Cii unsaturated alkyl optionally substituted with one or more hydroxyls. In embodiments, R 4 is Cii unsaturated alkyl with one double bond optionally substituted with one or more hydroxyls. In embodiments, x is one in A and E; and x is zero in D and E.
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- R 1 is H, or OH
- R 2 and R 3 are independently H, OH, or CH 2 OH;
- X is O or CHOH:
- R is C 3 -Ci 2 unsaturated alkyl.
- R 1 is OH.
- R 2 is H.
- X is CHOH.
- Y is CH 2 .
- R 3 is H.
- R 4 is a C to C 7 unsaturated alkyl. In embodiments, R 4 is a C5 unsaturated alkyl. In embodiments, R 4 is a C5 alkyl with one double bond.
- R 3 is OH.
- R 4 is a C 8 to C 12 unsaturated alkyl. In embodiments, R 4 is a C 10 unsaturated alkyl. In embodiments, R 4 is a C 10 alkyl with one double bond.
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- X is O or NH
- R 1 is H, OH, or CH 2 OH
- R 2 is H or OCOR 5 , wherein R 5 is a C C 3 alkyl
- R 3 is H or Ci-Cio saturated or unsaturated alkyl.
- X is O.
- R 1 is OH.
- R 2 is OCOR 5 .
- R 5 is CH 3 .
- R 3 is C 5 to C9 saturated or unsaturated alkyl, such as C 7 unsaturated alkyl.
- R 3 is C 7 alkyl with one double bond.
- X is NH. In some embodiments where X is NH, R 1 and R 2 are both H. In some embodiments where X is NH, R 3 is H.
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- X and Y are each independently C7-C 2 0 straight or branched chain unsaturated alkyl unsubstituted or substituted with one or more OH;
- A is saccharidyl
- R 10 and R 11 are each independently H, OH or saccharidyl.
- a, b, d, e, f and g are each independently zero or 1;
- X and Y are each independently C7-C 20 straight or branched chain unsaturated alkyl unsubstituted or substituted with one or more OH;
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are each independently H, OH, CH 3 , CH 2 CH 3 , and CH 2 OH;
- R 10 and R 11 are each independently H, OH or saccharidyl. diments, one or both of R 10 and R 11 are saccharidyl and are independently
- i, j and k are each independently zero or 1 , and
- R 12 , R 13 , R 14 , R 15 , R 16 , R 17 and R 18 are each independently H, OH, CH 3 , CH 2 CH 3 and CH 2 OH.
- X and Y are each independently straight or branched chain unsaturated alkyl unsubstituted or substituted with one or more OH and having 2 to 6 double bounds. In embodiments, X and Y are each independently C 10 -C 15 straight or branched chain unsaturated alkyl unsubstituted or substituted with one or more OH and having 2 to 4 double bounds.
- R 19 , R 20 , R 21 , R 22 and R 23 are each independently H, CH 3 or OH.
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- R 1 is H, or COR 4 where R 4 is H, or saturated or unsaturated Ci-C 6 straight or branched alkyl;
- R 2 , R 3 , R a , R b , R c , R d , R e , R f , R g , R h , R', and R j are independently selected from H, or saturated or unsaturated C 1 -C 3 alkyl.
- R 2 , R 3 , R a , R b , R c , R d , R e , R f , R g , R h , R', and R j are independently selected from
- R 2 is a saturated or unsaturated C 1 -C 3 alkyl, such as methyl.
- R 2 is a saturated or unsaturated C 1 -C 3 alkyl, such as methyl.
- R 3 is a saturated or unsaturated C 1 -C 3 alkyl, such as methyl.
- R 2 is CH 3 and R 3 [00280]
- R 1 is H.
- R 1 is COCH 3 .
- R 1 is COR 4 and R 4 is
- R 5 and R 6 are independently selected from H, or saturated or unsaturated C 1 -C4.
- R 5 and R 6 are both CH 3 .
- a compound according to Formula T is a compound where (i) R 2 , R 3 , R a , R b ,
- R c , R d , R e , R f , R g , R h , R 1 , and R j are independently selected from H, or saturated or unsaturated C 1 -C3 alkyl; and (ii) R 7 is H or saturated or unsaturated Ci-C 3 alkyl. In such embodiments, R 7 may be CH 3 .
- R 2 , R 3 , R a , R b , R c , R d , R e , R f , R g , R h , R', and R j may independently be selected from H, or saturated or unsaturated Ci-C 3 alkyl with the caveat that saturated or unsaturated Ci- C 3 alkyl substituents are not directly adjacent each other.
- R 2 may be a saturated or unsaturated Ci-C 3 alky, such as methyl.
- R 3 may be a saturated or unsaturated Ci-C 3 alkyl, such as methyl. In some of such embodiment, R 2 is CH 3 and R 3 is CH 3 .
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- R 2 , R 3 , R a , R b , R c , R d , R e , R f , R g , R h , R', and R j are independently selected from H, or saturated or unsaturated C 1 -C3 alkyl;
- R 7 is H or saturated or unsaturated C 1 -C3 alkyl.
- a bioactive, taste modulating, or salty taste modulating compound is a compound having the following structure:
- R 1 is H, OH, or C 1 -C 3 alkoxy
- R a , R b , R c , R d , and R e are each independently selected from: H, OH, alkoxy;
- R 3 is H, OH, C 1 -C3 alkoxy, or R 2 and R together form a ring structure as indicated above;
- R 4 is H, OH, or C 1 -C3 alkoxy
- X is O or CH
- R 6 , R 7 , and R 8 are each independently selected from: H, OH, or C 1 -C 3 alkoxy;
- R f , R g , R h , R', R j , and R k are each independently selected from: H, OH, or C 1 -C 3 alkoxy, wherein the at least one compound of formula U is present in the food product in an
- R 1 is H. In embodiments, R 1 is -OCH 3 . In embodiments, R 2 is H. In embodiments, R 3 is H. In embodiments, both R 2 and R 3 are H.
- R 4 is H.
- R a , R b , R c , R d , and R e are independently H or OH.
- R 8 may be OH.
- R f , R g , R h , R', R j , or R k may indepdently be H or OH.
- a compound according to Formula U is a compound having the following structure:
- R 1 , R 2 , R 3 , R 4 , R 6 , R 7 , and R 8 are each independently H, OH, or C 1 -C 3 alkoxy;
- X and Z are each independently O or CH;
- R a , R b , R c , R d , R e , R f , R g , R h , R', R j , and R K are each independently H, OH, or C 1 -C 3 alkoxy.
- a compound of Formula UA is a compound where R 1 is OH or C 1 -C 3 alkoxy.
- R 2 is H.
- R 3 is OH or C 1 -C 3 alkoxy.
- R 4 is OH or C 1 -C 3 alkoxy.
- R 6 is OH or C 1 -C 3 alkoxy.
- R 7 is OH or Ci- C 3 alkoxy.
- R a , R b , R c , R d , R e , R f , R g , R h , R', R j , and R k are each independently H or OH.
- R a , R b , R c , R d , R e , R f , R g , R h , R', R j , and R k are each H.
- X is O.
- Z is O.
- Table 2A lists the initially selected 99 compounds (with compounds 12 and 20 being the same compound isolated from different sources) and indicates which categories and subcategories, if appropriate, into which each of the compounds falls.
- Table 2B lists the categories and the compound that fall within each category.
- gingerols alkyl substituted phenols, acridone alcaloids, labdanes, primaranes, saponines, neolignans, pentacyclic triterpenes, 2,2'-cyclolignans, dibenzylbutane lignans, bicyclic triterpenes, phloroglucines, carylophyllenes, beta-carbolines, limnoids, cumarines, cardanolide steroids, fatty acids, and derivatives may be candidates for taste modulating compounds. It will be further understood that other structural similarities of the compounds presented herein may be exploited to develop taste modulating compounds.
- many of the compounds presented herein have unsaturated carbon chains of at least 11 carbons with attached hydroxyl groups and may be amphiphilic, with hydrophobic head potions and hydrophobic tails.
- Other compounds having, for example C5-C20 alkane or alkene tails may elicit or enhance saltiness.
- other compounds with differently substituted carboxyl or hydroxyl groups may elicit or enhance the perception of saltiness.
- a plurality of compounds presented herein include saturated carbon chains of at least 9 carbons and one oxygen containing group such as hydroxyl, carbonyl, carboxyl, or ester. Other compounds having unsaturated carbon chains of, for example, 5 to 15 carbons and an oxygen group may have similar effects with regard to salty taste.
- Many compounds presented herein have at least one phenol group with an ether group and a carbon side chain comprising at least seven carbons. Other similar compounds may have similar effects with regard to salty taste.
- a number of compounds presented herein have a benzyl heterocyclic furan with various attached groups containing unsaturated carbon linkages and at least one carbonyl group. Other similar compounds may have similar activity with regard to salty taste.
- a plurality of compounds presented above contain a cyclopentaphenthrene group.
- Other compounds having a cyclopentaphenthrene and similar substituents may have similar activity with regard to salty taste.
- a number of the compounds presented herein include a benzopyranone group.
- Other compounds having a benzopyranone and similar substituents may have similar activity with regard to salty taste.
- a plurality of compounds presented herein have a methoxymethyltetrahydrobenzo- cyclooctabenzo-dioxole or -annulene group. Other compounds having such groups may have similar activity with regard to salty taste.
- Many of the compounds can be classified as lactones, lignol-like compounds, oxylipins, polyisoprene glycosides, triterpenoid glycosides, alkylamides, or gamma pyrenes. Other similar compounds may also elicit or enhance salty taste perception.
- a DAP score of greater than 3.1 indicates saltiness or salt enhancement.
- the DAP score can be correlated with a sodium reduction potential by subtracting 3.1 from the DAP score.
- a DAP score of greater than 7.6 indicates saltiness or salt enhancement.
- the DAP score can be correlated with a sodium reduction potential by subtracting 7.6 from the DAP score.
Landscapes
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Seasonings (AREA)
- Seeds, Soups, And Other Foods (AREA)
- Grain Derivatives (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
- General Preparation And Processing Of Foods (AREA)
- Dairy Products (AREA)
- Confectionery (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18201716.0A EP3466930B1 (en) | 2013-02-08 | 2014-02-07 | Reduced sodium food product |
| ES14705458T ES2704880T3 (es) | 2013-02-08 | 2014-02-07 | Productos alimentarios reducidos en sodio |
| EP14705458.9A EP2984073B1 (en) | 2013-02-08 | 2014-02-07 | Reduced sodium food product |
| DK14705458.9T DK2984073T3 (en) | 2013-02-08 | 2014-02-07 | FOOD PRODUCT WITH REDUCED SODIUM |
| US14/820,891 US10159268B2 (en) | 2013-02-08 | 2015-08-07 | Reduced sodium food products |
| US16/197,550 US20190090520A1 (en) | 2013-02-08 | 2018-11-21 | Reduced sodium food products |
| US16/877,126 US20200281236A1 (en) | 2013-02-08 | 2020-05-18 | Reduced sodium food products |
Applications Claiming Priority (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361762798P | 2013-02-08 | 2013-02-08 | |
| US201361762781P | 2013-02-08 | 2013-02-08 | |
| US201361762804P | 2013-02-08 | 2013-02-08 | |
| US201361762792P | 2013-02-08 | 2013-02-08 | |
| US61/762,798 | 2013-02-08 | ||
| US61/762,804 | 2013-02-08 | ||
| US61/762,792 | 2013-02-08 | ||
| US61/762,781 | 2013-02-08 | ||
| US201361763300P | 2013-02-11 | 2013-02-11 | |
| US201361763274P | 2013-02-11 | 2013-02-11 | |
| US201361763244P | 2013-02-11 | 2013-02-11 | |
| US61/763,244 | 2013-02-11 | ||
| US61/763,274 | 2013-02-11 | ||
| US61/763,300 | 2013-02-11 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2014/015200 Continuation WO2014124193A1 (en) | 2013-02-08 | 2014-02-07 | Reduced sodium food products |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2014/015230 Continuation WO2014124214A1 (en) | 2013-02-08 | 2014-02-07 | Reduced sodium food products |
| PCT/US2014/015244 Continuation WO2014124222A1 (en) | 2013-02-08 | 2014-02-07 | Reduced sodium food products |
| US14/820,891 Continuation US10159268B2 (en) | 2013-02-08 | 2015-08-07 | Reduced sodium food products |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2014124191A1 true WO2014124191A1 (en) | 2014-08-14 |
Family
ID=50138012
Family Applications (13)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2014/015192 Ceased WO2014124191A1 (en) | 2013-02-08 | 2014-02-07 | Reduced sodium food product |
| PCT/US2014/015240 Ceased WO2014124220A1 (en) | 2013-02-08 | 2014-02-07 | Reduced sodium food product |
| PCT/US2014/015230 Ceased WO2014124214A1 (en) | 2013-02-08 | 2014-02-07 | Reduced sodium food products |
| PCT/US2014/015211 Ceased WO2014124201A1 (en) | 2013-02-08 | 2014-02-07 | Reduced sodium food products |
| PCT/US2014/015239 Ceased WO2014124219A1 (en) | 2013-02-08 | 2014-02-07 | Reduced sodium food product |
| PCT/US2014/015207 Ceased WO2014124198A1 (en) | 2013-02-08 | 2014-02-07 | Reduced sodium food product |
| PCT/US2014/015223 Ceased WO2014124209A1 (en) | 2013-02-08 | 2014-02-07 | Reduced sodium food products |
| PCT/US2014/015227 Ceased WO2014124212A1 (en) | 2013-02-08 | 2014-02-07 | Reduced sodium food products |
| PCT/US2014/015234 Ceased WO2014124216A1 (en) | 2013-02-08 | 2014-02-07 | Reduced sodium food product |
| PCT/US2014/015216 Ceased WO2014124205A1 (en) | 2013-02-08 | 2014-02-07 | Reduced sodium food products |
| PCT/US2014/015200 Ceased WO2014124193A1 (en) | 2013-02-08 | 2014-02-07 | Reduced sodium food products |
| PCT/US2014/015220 Ceased WO2014124207A1 (en) | 2013-02-08 | 2014-02-07 | Reduced sodium food products |
| PCT/US2014/015244 Ceased WO2014124222A1 (en) | 2013-02-08 | 2014-02-07 | Reduced sodium food products |
Family Applications After (12)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2014/015240 Ceased WO2014124220A1 (en) | 2013-02-08 | 2014-02-07 | Reduced sodium food product |
| PCT/US2014/015230 Ceased WO2014124214A1 (en) | 2013-02-08 | 2014-02-07 | Reduced sodium food products |
| PCT/US2014/015211 Ceased WO2014124201A1 (en) | 2013-02-08 | 2014-02-07 | Reduced sodium food products |
| PCT/US2014/015239 Ceased WO2014124219A1 (en) | 2013-02-08 | 2014-02-07 | Reduced sodium food product |
| PCT/US2014/015207 Ceased WO2014124198A1 (en) | 2013-02-08 | 2014-02-07 | Reduced sodium food product |
| PCT/US2014/015223 Ceased WO2014124209A1 (en) | 2013-02-08 | 2014-02-07 | Reduced sodium food products |
| PCT/US2014/015227 Ceased WO2014124212A1 (en) | 2013-02-08 | 2014-02-07 | Reduced sodium food products |
| PCT/US2014/015234 Ceased WO2014124216A1 (en) | 2013-02-08 | 2014-02-07 | Reduced sodium food product |
| PCT/US2014/015216 Ceased WO2014124205A1 (en) | 2013-02-08 | 2014-02-07 | Reduced sodium food products |
| PCT/US2014/015200 Ceased WO2014124193A1 (en) | 2013-02-08 | 2014-02-07 | Reduced sodium food products |
| PCT/US2014/015220 Ceased WO2014124207A1 (en) | 2013-02-08 | 2014-02-07 | Reduced sodium food products |
| PCT/US2014/015244 Ceased WO2014124222A1 (en) | 2013-02-08 | 2014-02-07 | Reduced sodium food products |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US11540539B2 (enExample) |
| EP (7) | EP2953934B1 (enExample) |
| JP (6) | JP2016509830A (enExample) |
| CN (4) | CN111557432B (enExample) |
| BR (2) | BR112015018948A2 (enExample) |
| CA (3) | CA2900707C (enExample) |
| DK (7) | DK3366677T3 (enExample) |
| ES (7) | ES2675215T3 (enExample) |
| FI (1) | FI3732994T3 (enExample) |
| PT (7) | PT3732994T (enExample) |
| WO (13) | WO2014124191A1 (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021094268A1 (en) * | 2019-11-11 | 2021-05-20 | Firmenich Sa | Gingerol compounds and their use as flavor modifiers |
| WO2021175751A1 (en) * | 2020-03-05 | 2021-09-10 | Firmenich Sa | 11-oxo-cucurbitanes and their use as flavor modifiers |
| CN113582981A (zh) * | 2021-07-08 | 2021-11-02 | 中国科学院昆明植物研究所 | 一类新颖二芳基庚烷-黄烷酮杂合体及其药物组合物和应用 |
| WO2022214275A1 (en) * | 2021-04-06 | 2022-10-13 | Firmenich Sa | Use of gingerdiol compounds to enhance flavor |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111557432B (zh) * | 2013-02-08 | 2023-08-04 | 通用磨坊公司 | 低钠食品 |
| CN105384721A (zh) * | 2015-12-07 | 2016-03-09 | 西宁意格知识产权咨询服务有限公司 | 新的联苯环辛烯型木脂素类化合物及其制备方法和用途 |
| KR102836360B1 (ko) | 2016-04-15 | 2025-07-23 | 베크만 컬터, 인코포레이티드 | 광활성 거대분자 및 그의 용도 |
| US11040942B1 (en) | 2018-01-31 | 2021-06-22 | University Of Oregon | Compound embodiments for hydrogen sulfide production and methods of making and using the same |
| US11078157B1 (en) | 2018-01-31 | 2021-08-03 | University Of Oregon | Compound embodiments that release H2S by reaction with a reactive compound and methods of making and using the same |
| US11700869B2 (en) * | 2018-06-27 | 2023-07-18 | Pepsico, Inc. | Mouthfeel enhancing composition |
| EP3756474B1 (en) | 2019-06-25 | 2024-03-06 | Analyticon Discovery GmbH | An extract of persea |
| US20220218007A1 (en) * | 2021-01-14 | 2022-07-14 | Raghavi Kantharuban | Methods and composition to reduce salt in food products |
| US20220248732A1 (en) * | 2021-02-05 | 2022-08-11 | Frito-Lay North America, Inc. | Saltiness-Perception Enhancing Compounds |
| JP2023073794A (ja) * | 2021-11-16 | 2023-05-26 | ハウスウェルネスフーズ株式会社 | アドレノメデュリン遺伝子発現増強用組成物 |
| EP4454482A1 (en) | 2023-04-26 | 2024-10-30 | Analyticon Discovery GmbH | Preparations comprising oleanol glycosides |
| WO2025090617A1 (en) * | 2023-10-23 | 2025-05-01 | Monell Chemical Senses Center | Compositions and methods for the identification of salt alternatives |
| WO2025090573A1 (en) * | 2023-10-23 | 2025-05-01 | Ohio State Innovation Foundation | Heat and pain suppressing compounds |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010124905A1 (en) * | 2009-04-29 | 2010-11-04 | Akzo Nobel Chemicals International B.V. | Process to prepare a low-sodium salt product, product obtainable thereby and the use thereof |
Family Cites Families (292)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4160862A (en) | 1972-06-12 | 1979-07-10 | Sterling Drug Inc. | 1-Acyl-3-(amino-lower-alkyl)indoles |
| JPS5810429A (ja) | 1981-07-07 | 1983-01-21 | Inoue Japax Res Inc | ワイヤカツト放電加工方法 |
| JPS58212764A (ja) * | 1982-06-03 | 1983-12-10 | Sadao Nakayama | 調味組成物類とその利用食品 |
| HU194220B (en) | 1985-04-19 | 1988-01-28 | Richter Gedeon Vegyeszet | Process for production of derivatives of 1,12 b disubstituated-octahydro-indolo /2,3-a/ quinolisine and medical compounds containing thereof |
| US4997672A (en) * | 1987-03-10 | 1991-03-05 | Virginia Commonwealth University | Salt taste enhancer |
| DE3924607A1 (de) | 1989-07-21 | 1991-01-24 | Singer Peter Dr Sc Med | Diaetetisches nahrungs- oder genussmittel |
| JPH03161470A (ja) | 1989-11-17 | 1991-07-11 | Nisshin Flour Milling Co Ltd | インドール誘導体 |
| US5232684A (en) | 1990-06-29 | 1993-08-03 | The United States Of America As Represented By The Department Of Health And Human Services | Labelled resiniferatoxin, compositions thereof, and methods for using the same |
| US5874479A (en) | 1991-03-01 | 1999-02-23 | Warner-Lambert Company | Therapeutic permeation enhanced-wound healing compositions and methods for preparing and using same |
| DE4217842A1 (de) | 1992-05-29 | 1993-12-02 | Dietl Hans | Calciumantagonisten enthaltende pharmazeutische Zubereitung zur intravenösen und intrakoronaren Applikation sowie Verfahren zu ihrer Herstellung |
| US5260091A (en) * | 1992-10-21 | 1993-11-09 | Interneuron Pharmaceuticals Inc. | Salt taste enhancers |
| WO1994010165A1 (en) | 1992-10-28 | 1994-05-11 | Merck Sharp & Dohme Limited | 4-arylmethyloxymethyl piperidines as tachykinin antagonists |
| US5648365A (en) | 1993-01-21 | 1997-07-15 | Merrell Pharmaceuticals Inc. | Diarylalkyl piperidines useful as multi-drug resistant tumor agents |
| US5719148A (en) | 1993-10-15 | 1998-02-17 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
| JP3014575B2 (ja) | 1993-10-29 | 2000-02-28 | 寳酒造株式会社 | 呈味改良剤 |
| US5494919A (en) | 1993-11-09 | 1996-02-27 | Merck & Co., Inc. | 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
| JP3575705B2 (ja) | 1994-08-02 | 2004-10-13 | 小川香料株式会社 | ジンゲロールおよびショーガオールの製造法 |
| JPH10503768A (ja) | 1994-08-02 | 1998-04-07 | メルク シヤープ エンド ドーム リミテツド | アゼチジン、ピロリジンおよびピペリジン誘導体 |
| US6221669B1 (en) | 1994-10-19 | 2001-04-24 | Lifecell Corporation | Prolonged preservation of blood platelets |
| US5919614A (en) | 1994-10-19 | 1999-07-06 | Lifecell Corporation | Composition comprising three platelet lesion inhibitors for platelet storage |
| CA2207201A1 (en) | 1994-12-06 | 1996-06-13 | Caroline Henry | Azetidine, pyrrolidine and piperidine derivatives as 5ht1 receptor agonists |
| US5700806A (en) | 1995-03-24 | 1997-12-23 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
| TW453881B (en) | 1995-10-16 | 2001-09-11 | Kao Corp | Cosmetic composition comprising amide derivatives |
| NZ321575A (en) | 1995-10-30 | 1999-05-28 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives |
| GB9523243D0 (en) | 1995-11-14 | 1996-01-17 | Merck Sharp & Dohme | Therapeutic agents |
| TW429256B (en) | 1995-12-27 | 2001-04-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives |
| JP3549366B2 (ja) | 1996-06-20 | 2004-08-04 | 株式会社林原生物化学研究所 | 飲食物の塩から味及び/又は旨味増強方法 |
| ATE321882T1 (de) | 1997-07-01 | 2006-04-15 | Isis Pharmaceuticals Inc | Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre |
| GB9807607D0 (en) | 1998-04-08 | 1998-06-10 | Bp Chem Int Ltd | Fuel additive |
| US6303620B1 (en) | 1998-05-11 | 2001-10-16 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| CA2329130A1 (en) | 1998-05-21 | 1999-11-25 | Isis Pharmaceuticals Inc. | Compositions and methods for non-parenteral delivery of oligonucleotides |
| US6841539B1 (en) | 1998-05-21 | 2005-01-11 | Isis Pharmaceuticals, Inc. | Compositions and methods for topical delivery of oligonucleotides |
| US5948460A (en) | 1998-07-27 | 1999-09-07 | Takasago International Corporation | Flavored product additive and method for using same |
| JP4267783B2 (ja) | 1998-10-02 | 2009-05-27 | 株式会社インテリジェントセンサーテクノロジー | 味認識装置 |
| WO2000053545A1 (en) | 1999-03-10 | 2000-09-14 | Axys Pharmaceuticals, Inc. | Process for the synthesis of dihydropyridones |
| US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
| RU2164766C1 (ru) * | 1999-10-22 | 2001-04-10 | Емец Юрий Алексеевич | Биологически активная добавка к пище |
| ATE262283T1 (de) | 2000-02-10 | 2004-04-15 | Loders Croklaan Bv | Fettmischungen mit kristallmodifikatoren |
| GB0003397D0 (en) | 2000-02-14 | 2000-04-05 | Merck Sharp & Dohme | Therapeutic agents |
| JP3394737B2 (ja) | 2000-03-03 | 2003-04-07 | 正田醤油株式会社 | 低塩醤油調味料 |
| DE20008343U1 (de) | 2000-05-09 | 2000-09-14 | Abatu, Fuat, 46242 Bottrop | Gewürzmischung |
| DE60114708T2 (de) | 2000-06-05 | 2006-07-20 | Loders Croklaan B.V. | Ursolsäure und Oleanolsäure enthaltende Mischungen |
| GB0023918D0 (en) * | 2000-09-29 | 2000-11-15 | King S College London | Antiparasitic compounds |
| JP2002125616A (ja) | 2000-10-27 | 2002-05-08 | Apio Club:Kk | ハーブソルトの製造方法 |
| US20120237626A9 (en) | 2000-12-05 | 2012-09-20 | Palu Afa Kehaati | Profiles of lipid proteins and inhibiting HMG-CoA reductase |
| JP4277294B2 (ja) | 2000-12-26 | 2009-06-10 | 佐藤食品工業株式会社 | 食品の風味改良方法 |
| JP4360807B2 (ja) * | 2001-04-05 | 2009-11-11 | 協和発酵バイオ株式会社 | 肝機能保護または改善剤 |
| AU772384B2 (en) * | 2001-05-09 | 2004-04-29 | Nestec S.A. | Vitex agnus castus extract |
| JP2002345430A (ja) | 2001-05-28 | 2002-12-03 | Kyowa Hakko Kogyo Co Ltd | 食塩味増強方法、食塩味増強剤、食塩味調味料および食塩味増強飲食品 |
| JP2002370922A (ja) | 2001-06-15 | 2002-12-24 | Azuma Noen:Kk | 梅抽出物を含む化粧品 |
| WO2003008632A1 (en) | 2001-07-16 | 2003-01-30 | Hoegestaett Edward | Fatty acid conjugation as a method for screening of potentially bioactive substances |
| US6821998B2 (en) | 2001-08-30 | 2004-11-23 | Chemocentryx, Inc. | Arylamines as inhibitors of chemokine binding to US28 |
| JP4278896B2 (ja) | 2001-11-02 | 2009-06-17 | 丸善製薬株式会社 | ヒハツ果穂抽出物組成物及びヒハツ果穂抽出物含有飲食物並びにヒハツ果穂抽出物の呈味改善方法 |
| CN1347664A (zh) | 2001-11-07 | 2002-05-08 | 林泽垠 | 天然无盐咸味食物添加剂及其制备方法 |
| US6743461B1 (en) * | 2001-11-09 | 2004-06-01 | Ecosalt Corporation | Salt substitute compositions |
| CN1435123A (zh) | 2002-02-01 | 2003-08-13 | 冯旭斌 | 轧海椒 |
| OA12790A (en) | 2002-03-13 | 2006-07-10 | Janssen Pharmaceutica Nv | New inhibitors of histone deacetylase. |
| US6929809B2 (en) | 2002-03-26 | 2005-08-16 | Council Of Scientific And Industrial Research | Preparation of nutrient rich salt of plant origin |
| US6691780B2 (en) | 2002-04-18 | 2004-02-17 | Halliburton Energy Services, Inc. | Tracking of particulate flowback in subterranean wells |
| WO2003092676A1 (en) | 2002-04-29 | 2003-11-13 | The General Hospital Corporation | Compositions and methods for preventing abuse of orally administered medications |
| MY141736A (en) | 2002-10-08 | 2010-06-15 | Elanco Animal Health Ireland | Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists |
| US20100173993A1 (en) | 2003-02-06 | 2010-07-08 | Sawyer Anthony J | Controlled release biocidal salts |
| GB0306399D0 (en) | 2003-03-20 | 2003-04-23 | Ineos Fluor Holdings Ltd | Process for reducing the concentration of undesired compounds in a composition |
| US20040202735A1 (en) | 2003-04-08 | 2004-10-14 | Moore Bob M. | Method and kit for controlling bleeding |
| JP2006527236A (ja) | 2003-06-10 | 2006-11-30 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | オピオイド鎮痛薬と組合せた置換1,4−ジ−ピペリジン−4−イル−ピペラジン誘導体ならびに疼痛およびオピオイドに基づく処置に伴う副作用の処置のためのそれらの使用 |
| DE602004013772D1 (de) | 2003-06-10 | 2008-06-26 | Janssen Pharmaceutica Nv | Kombination von opioiden und einem piperazin-derivat für die behandlung von schmerzen |
| US20080060576A1 (en) | 2003-06-27 | 2008-03-13 | Sumitomo Electric Industries, Ltd. | Wafer Holder for Semiconductor Manufacturing Device and Semiconductor Manufacturing Device in Which It Is Installed |
| JP2005013138A (ja) | 2003-06-27 | 2005-01-20 | Kiyomitsu Kawasaki | 香辛料フレーバーの製造方法 |
| JP2005015684A (ja) | 2003-06-27 | 2005-01-20 | Kiyomitsu Kawasaki | 野菜フレーバーの製造方法 |
| US20050031717A1 (en) | 2003-07-09 | 2005-02-10 | Desimone John A. | Salt taste modification |
| ATE472256T1 (de) | 2003-07-10 | 2010-07-15 | Takasago Perfumery Co Ltd | Geschmacksverstärker, nahrungsmittel- oder getränkeprodukt, das den geschmacksverstärker enthält sowie geschmacksverstärkungsverfahren |
| US20050025844A1 (en) | 2003-08-02 | 2005-02-03 | Matthias Boldt | Weight control compositions and methods |
| US7846422B2 (en) | 2003-08-04 | 2010-12-07 | Kao Corporation | Method for prevention or treatment of periodontal diseases and composition for an oral cavity |
| CL2004002050A1 (es) | 2003-08-13 | 2005-06-03 | Pharmacia Corp Sa Organizada B | Compuestos derivados de piridinonas sustituidas; su uso en el tratamiento de afecciones causadas o exacerbadas por actividad p38 map kinasa y/o tnf no regulada, tales como inflamaciones, tumores, sida y otros. |
| JP4926707B2 (ja) | 2003-08-22 | 2012-05-09 | ダニスコ エイ/エス | 封入化抗菌材料 |
| GB2388581A (en) | 2003-08-22 | 2003-11-19 | Danisco | Coated aqueous beads |
| JP2005075785A (ja) | 2003-09-01 | 2005-03-24 | Japan Science & Technology Agency | ピペリジン誘導体及びその製造方法 |
| US20070093552A1 (en) | 2003-09-22 | 2007-04-26 | Futoshi Matsuyama | Early insulin secretion stimulator |
| US20070059351A1 (en) | 2003-10-17 | 2007-03-15 | Murrell George A C | Transdermal patches containing a nitric oxide-donor and a second active agent and associated methods |
| CN100391364C (zh) * | 2003-10-30 | 2008-06-04 | 张湘生 | 调味香辛料 |
| TWI356681B (en) | 2003-11-12 | 2012-01-21 | J Oil Mills Inc | Body taste improver comprising long-chain highly u |
| US8389031B2 (en) | 2005-05-23 | 2013-03-05 | Kraft Foods Global Brands Llc | Coated delivery system for active components as part of an edible composition |
| PL1694320T3 (pl) | 2003-12-19 | 2008-11-28 | Lipid Nutrition Bv | Zastosowanie kompozycji zawierających kwas oleanolowy i kwas ursolowy do wytwarzania leku do leczenia nadwrażliwości i nadreaktywności |
| EP1720874A4 (en) | 2004-02-24 | 2010-03-03 | Bioaxone Therapeutique Inc | 4-SUBSTITUTED PIPERIDINE DERIVATIVES |
| US20050215635A1 (en) * | 2004-03-08 | 2005-09-29 | Rafi M Mohamed | Diarylheptanoid compounds and uses thereof |
| JP2007531769A (ja) | 2004-03-30 | 2007-11-08 | サファイア セラピューティクス インコーポレイテッド | 成長ホルモン分泌促進薬を使用したc−反応性蛋白質の低減方法 |
| JP2005298449A (ja) | 2004-04-15 | 2005-10-27 | Astellas Pharma Inc | 4−アミノピリミジン誘導体 |
| US20050272772A1 (en) | 2004-06-03 | 2005-12-08 | Burbaum Jonathan J | Pharmaceutical compositions for the treatment of pruritus |
| KR20050122373A (ko) | 2004-06-24 | 2005-12-29 | 대한민국(서울대학교 총장) | 단삼 뿌리 추출물 또는 디메틸 리소스퍼메이트 b를함유하는 나트륨 채널 촉진용 조성물 |
| JP4993407B2 (ja) | 2004-08-04 | 2012-08-08 | 大正製薬株式会社 | トリアゾール誘導体 |
| DE102004038396A1 (de) | 2004-08-06 | 2006-03-30 | Lothar Sellin | Vorrichtung zur Beschichtung von Medizinprodukten |
| CA2576375C (en) | 2004-08-11 | 2010-12-21 | Cadbury Adams Usa Llc | Sensate compositions and delivery systems therefor |
| EP1789067B8 (en) | 2004-08-12 | 2012-08-15 | Helsinn Healthcare S.A. | Use of growth hormone secretagogues for stimulating the motility of the gastrointestinal system |
| US20060135441A1 (en) | 2004-09-02 | 2006-06-22 | Bionaut Pharmaceuticals, Inc. | Combinatorial chemotherapy treatment using Na+/K+ ATPase inhibitors |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| EP1796675A4 (en) | 2004-10-01 | 2009-03-04 | Merck & Co Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISEASES |
| US20060135443A1 (en) | 2004-10-18 | 2006-06-22 | Bionaut Pharmaceuticals, Inc. | Use of Na*/K*-ATPase inhibitors and antagonists thereof |
| JP2006124322A (ja) | 2004-10-28 | 2006-05-18 | Takasago Internatl Corp | ヒアルロニダーゼ阻害剤、および該ヒアルロニダーゼ阻害剤を含有する皮膚外用組成物および口腔用組成物 |
| US20080103202A1 (en) | 2004-11-08 | 2008-05-01 | Chris Ferguson | Method of preparing creatine ester salts and uses thereof. |
| MX2007006324A (es) * | 2004-11-29 | 2007-10-17 | Aloecorp Inc | Deshidratacion de combinaciones de alimentos. |
| WO2006060505A2 (en) | 2004-12-01 | 2006-06-08 | Dacanay Rhodel G | Capsaicin nutritional supplement |
| JP4942141B2 (ja) | 2004-12-02 | 2012-05-30 | 江崎グリコ株式会社 | カルボキシル基への糖転移方法 |
| ES2355109T3 (es) | 2004-12-22 | 2011-03-22 | Mestex Ag | Mezcla de un agonista de receptor de vainilloide con una sustancia inhibidora de la regeneración nerviosa, su utilización para la fabricación de un analgésico y procedimiento de aplicación de este fármaco. |
| WO2006069452A1 (de) | 2004-12-28 | 2006-07-06 | Mestex Ag | Verwendung eines vanilloidrezeptoragonisten zusammen mit einem glycosaminoglycan oder proteoglycan für die herstellung eines mittels zur behandlung von gelenkschmerzen und verfahren zur applikation dieses mittels |
| EP1871179B1 (en) | 2005-01-28 | 2018-06-06 | Archer Daniels Midland Company | Animal feed compositions capable of reducing the incidence of fescue toxicosis in mammals |
| ATE374604T1 (de) | 2005-02-18 | 2007-10-15 | Procter & Gamble | Coffein enthaltendes konfekt |
| US20060198806A1 (en) | 2005-03-04 | 2006-09-07 | Reilly Christopher A | Capsaicinoid decontamination compositions and methods of use |
| JP2006238814A (ja) | 2005-03-04 | 2006-09-14 | Ogawa & Co Ltd | 風味増強剤、調味料及びこれらを含有する飲食物並びに風味増強方法 |
| EP1859035B1 (en) | 2005-03-08 | 2016-01-13 | Agency for Science, Technology and Research | Immobilised enzymes |
| US20060204601A1 (en) | 2005-03-09 | 2006-09-14 | Palu Afa K | Formulations and methods for preventing and treating substance abuse and addiction |
| JP2006246857A (ja) | 2005-03-14 | 2006-09-21 | Showa Sangyo Co Ltd | 油脂組成物、並びに食品 |
| WO2006107832A2 (en) | 2005-04-05 | 2006-10-12 | President And Fellows Of Harvard College | Methods and kits for isolating nucleic acids |
| JP4508932B2 (ja) | 2005-04-25 | 2010-07-21 | 小川香料株式会社 | 呈味増強剤及び該呈味増強剤を含有する香味料並びに該香味料を含有する飲食物 |
| ES2399059T3 (es) | 2005-05-23 | 2013-03-25 | Kraft Foods Global Brands Llc | Composiciones potenciadoras del dulzor |
| CN1736485A (zh) | 2005-06-29 | 2006-02-22 | 上海美迪西生物医药有限公司 | 香草醛受体激动剂用于制备抗阿尔茨海默病产品的用途 |
| WO2007018508A1 (en) | 2005-07-28 | 2007-02-15 | Glaxo Group Limited | Novel m3 muscarinic acetycholine receptor antagonists |
| WO2007018514A1 (en) | 2005-07-28 | 2007-02-15 | Glaxo Group Limited | Novel m3 muscarinic acetylcholine receptor antagonists |
| GB0520845D0 (en) | 2005-10-14 | 2005-11-23 | Hofmann Thomas F | Salt enhancing compounds and use |
| US9125833B2 (en) | 2005-11-02 | 2015-09-08 | Relmada Therapeutics, Inc. | Multimodal abuse resistant and extended release opioid formulations |
| US20070184137A1 (en) | 2005-11-29 | 2007-08-09 | Palu Afa K | Morinda Citrifolia L. Based Formulations for Inhibiting Matrix Metalloproteinase Enzymes |
| CN100490870C (zh) | 2006-01-13 | 2009-05-27 | 东莞广发制药有限公司 | 补脾益肾制剂及其制备方法与检验方法 |
| RU2395499C2 (ru) | 2006-02-06 | 2010-07-27 | Тайсо Фармасьютикал Ко., Лтд. | Ингибитор связывания сфингозин-1-фосфата |
| JP2007232574A (ja) | 2006-03-01 | 2007-09-13 | Ajinomoto Co Inc | 交感神経賦活物質のスクリーニング方法 |
| CN1820646A (zh) | 2006-03-11 | 2006-08-23 | 刘仁虎 | 含鸡屎藤的保健食品 |
| CN1857586A (zh) | 2006-03-28 | 2006-11-08 | 石圣洪 | 一种治疗骨质疏松症的中药制剂及其制备方法 |
| CN1857343A (zh) | 2006-04-11 | 2006-11-08 | 徐蕾 | 一种防治病毒性感冒及咽喉疾病的中药组合物及其制备方法 |
| US20070248621A1 (en) | 2006-04-24 | 2007-10-25 | Metabev Llc | Food product containing policosanols |
| CA2544227A1 (en) | 2006-04-20 | 2007-10-20 | Metabev Inc. | Food product containing policosanols |
| US8916611B2 (en) | 2006-04-28 | 2014-12-23 | Warsaw Orthopedic, Inc. | Pharmaceutical removal of neuronal extensions from a degenerating disc |
| US9789161B2 (en) | 2006-04-28 | 2017-10-17 | Warsaw Orthopedic, Inc. | Methods for treating back or neck pain caused by NGF using a therapeutic agent consisting of ReN-1820, ALE-0540 and capsaicin |
| US20070287991A1 (en) | 2006-06-08 | 2007-12-13 | Mckay William F | Devices and methods for detection of markers of axial pain with or without radiculopathy |
| JP2008000005A (ja) * | 2006-06-20 | 2008-01-10 | Shizuoka Prefecture | 嚥下障害改善剤および嚥下障害改善食品 |
| JP5265142B2 (ja) * | 2006-06-21 | 2013-08-14 | 株式会社Adeka | 塩味強化剤を含有する食塩組成物 |
| CN101095800A (zh) | 2006-06-29 | 2008-01-02 | 朱靖华 | 一种用于治疗口腔溃疡的贴片的研制 |
| WO2008011083A2 (en) | 2006-07-18 | 2008-01-24 | Cornell Research Foundation, Inc. | Compounds for enhancing arginase activity and methods of use thereof |
| WO2008021394A2 (en) | 2006-08-15 | 2008-02-21 | Theraquest Biosciences, Llc | Pharmaceutical formulations of cannabinoids and method of use |
| WO2008024490A2 (en) | 2006-08-24 | 2008-02-28 | Theraquest Biosciences, Inc. | Oral pharmaceutical formulations of abuse deterrent cannabinoids and method of use |
| WO2008027442A2 (en) | 2006-08-30 | 2008-03-06 | Theraquest Biosciences, Llc | Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use |
| WO2008033351A2 (en) | 2006-09-11 | 2008-03-20 | Theraquest Biosciences, Inc. | Multimodal abuse resistant and extended release formulations |
| ES2365263T3 (es) | 2006-10-04 | 2011-09-27 | Unilever N.V. | Extracto de tomate fraccionado potenciador del sabor y composiciones que lo comprenden. |
| US8058243B2 (en) | 2006-10-13 | 2011-11-15 | Hsc Research And Development Limited Partnership | Method for treating a brain cancer with ifenprodil |
| US20080124753A1 (en) | 2006-11-15 | 2008-05-29 | Lee Seunghun Paul | SpiceMatrix Technology for Taste Compound Identification |
| JP2010510227A (ja) | 2006-11-20 | 2010-04-02 | プレジデント アンド フェロウズ オブ ハーバード カレッジ | 痛みおよび痒みの治療方法、組成物およびキット |
| US20100068221A1 (en) | 2006-12-07 | 2010-03-18 | Arie Gerrit Terdu | Low salt food with improved taste |
| CA2671190A1 (en) | 2006-12-07 | 2008-06-12 | Dsm Ip Assets B.V. | Low salt food with improved taste |
| US20090312255A1 (en) | 2006-12-14 | 2009-12-17 | The Hospital For Sick Children | Stimulation of trpv1+ sensory neurons to control beta-cell stress and islet inflammation in diabetes |
| CN101562986A (zh) * | 2006-12-19 | 2009-10-21 | 帝斯曼知识产权资产管理有限公司 | 具有改善的口味的盐降低的乳制品 |
| CN101686966A (zh) | 2007-02-13 | 2010-03-31 | 赫尔辛医疗(美国)有限公司 | 使用生长激素促分泌素治疗细胞增生疾病的方法 |
| WO2008100977A2 (en) | 2007-02-14 | 2008-08-21 | N.V. Organon | Carbamates therapeutic release agents as amidase inhibitors |
| US20080199595A1 (en) * | 2007-02-15 | 2008-08-21 | Mccormick & Company | Salt replacing composition, process for its preparation and food systems containing such composition |
| US20090155180A1 (en) | 2007-02-28 | 2009-06-18 | Mary Lynn Jump | Methods and targets for identifying compounds for regulating rhinovirus infection |
| ES2599634T3 (es) | 2007-03-22 | 2017-02-02 | Ecosalt Corporation | Composición de sal baja en sodio o sin sodio que no es amarga |
| US20130115320A1 (en) | 2007-03-30 | 2013-05-09 | Dynova Laboratories, Inc. | Therapeutic agent for intranasal administration and method of making and using same |
| US20130115321A1 (en) | 2007-03-30 | 2013-05-09 | Dynova Laboratories, Inc. | Therapeutic agent for intranasal administration and method of making and using same |
| US20080241117A1 (en) | 2007-04-02 | 2008-10-02 | Abdul Gaffar | Oral Care Compositions Containing a Mixed Tocopherol Component |
| JP5576265B2 (ja) | 2007-04-05 | 2014-08-20 | ジボダン エス エー | 発酵成分 |
| CN101652078B (zh) | 2007-04-09 | 2016-04-13 | 日本烟草产业株式会社 | 调料组合物、类咸味呈味增强剂及饮食品的类咸味呈味增强方法 |
| TWI429436B (zh) | 2007-04-10 | 2014-03-11 | Helsinn Therapeutics Us Inc | 使用生長激素促泌素治療或預防嘔吐之方法 |
| US20080268001A1 (en) | 2007-04-30 | 2008-10-30 | Lynette Zaidel | Oral care composition to reduce or eliminate dental sensitivity |
| US20080267891A1 (en) | 2007-04-30 | 2008-10-30 | Colgate-Palmolive Company | Oral Care Composition To Reduce Or Eliminate Dental Sensitivity |
| WO2008139152A1 (en) | 2007-05-11 | 2008-11-20 | Sentinel Oncology Limited | N-oxide-containing pharmaceutical compounds |
| KR100784229B1 (ko) | 2007-05-17 | 2007-12-11 | 주식회사 파이토코 | 퉁퉁마디 유래의 소금 대체물 및 그 제조방법 |
| DE502008002360D1 (de) | 2007-06-19 | 2011-03-03 | Symrise Ag | Aromakomposition zum Verringern oder Unterdrücken von unerwünschtem bitteren und adstringierenden Eindruck |
| EP2011495A1 (en) | 2007-07-03 | 2009-01-07 | Sygnis Bioscience GmbH & Co. KG | Use of piperine and derivatives thereof for the therapy of neurological conditions |
| KR100891935B1 (ko) | 2007-07-10 | 2009-04-08 | 박양순 | 기능성 식혜제조방법 |
| KR100903739B1 (ko) | 2007-08-24 | 2009-06-19 | 씨제이제일제당 (주) | 과립형 조미소금 및 이의 제조방법 |
| EP2200454A1 (en) * | 2007-09-13 | 2010-06-30 | Firmenich S.A. | Flavoring compositions for savory applications |
| EP2042043A1 (en) | 2007-09-26 | 2009-04-01 | Nestec S.A. | A shelf-stable taste enhancing cultured savoury base and a process for its preparation |
| WO2009045504A1 (en) | 2007-10-04 | 2009-04-09 | President And Fellows Of Harvard College | Methods and compositions for treating cancer and modulating signal transduction and metabolism pathways |
| CL2007002915A1 (es) | 2007-10-10 | 2008-04-25 | Cox Y Compania S A | Composicion para alimentos, suplementos nutritivos, productos nutraceuticos u otros de consumo humano que comprende cloruro de sodio, cloruro de potasio, acidos y edulcorantes, donde las proporciones de dichos componentes confieren a la composicion p |
| CA2704778C (en) | 2007-11-05 | 2014-04-29 | Scolr Pharma, Inc. | Formulations for enhanced bioavailability of orally administered polar agents |
| JP2011504172A (ja) | 2007-11-19 | 2011-02-03 | ネステク ソシエテ アノニム | 口腔咽頭嚥下障害の治療 |
| WO2009071095A2 (en) | 2007-12-05 | 2009-06-11 | Neurokey A/S | Prevention of hyperthermia subsequent to hypothermia treatment of ischemia |
| WO2009071096A2 (en) | 2007-12-05 | 2009-06-11 | Neurokey A/S | Combination of medical and physical cooling treatment of ischemic effects |
| WO2009071094A2 (en) | 2007-12-05 | 2009-06-11 | Neurokey A/S | Combination treatment of ischemic effects |
| CN101254226B (zh) | 2007-12-19 | 2011-01-19 | 游洪涛 | 一种都梁复方中药软胶囊 |
| CA2708184C (en) | 2007-12-21 | 2016-05-03 | Unilever Plc | Tomato product and process to prepare the same |
| CN101214278B (zh) | 2007-12-26 | 2012-06-27 | 沈阳药科大学 | 提取五味子总木脂素的原料及制备工艺和用途 |
| US9259006B2 (en) | 2008-01-30 | 2016-02-16 | Smartwash Solutions, Llc | Antimicrobial compositions and methods of use thereof |
| ES2424632T3 (es) | 2008-02-24 | 2013-10-07 | Lycored Ltd. | El uso de sólidos solubles de tomate para reducir el contenido de sal de productos alimenticios |
| CA2717042A1 (en) * | 2008-03-11 | 2009-09-17 | The General Hospital Corporation | Methods, compositions, and kits for treating pain and pruritis |
| EP2625967B1 (en) | 2008-03-17 | 2015-07-01 | Givaudan SA | Enzymatic process for the provision of salt-enhancing ingredient |
| JP5596536B2 (ja) | 2008-03-24 | 2014-09-24 | 日本水産株式会社 | 塩味増強剤及びそれを含有する飲食品 |
| WO2009124551A2 (en) | 2008-04-09 | 2009-10-15 | Neurokey A/S | Use of hypothermia inducing drugs |
| WO2009124552A2 (en) | 2008-04-09 | 2009-10-15 | Neurokey A/S | Use of a combination of hypothermia inducing drugs |
| WO2009132342A1 (en) | 2008-04-25 | 2009-10-29 | Nanobio Corporation | Nanoemulsions for treating fungal, yeast and mold infections |
| WO2009140568A1 (en) * | 2008-05-15 | 2009-11-19 | The Coca-Cola Company | Natural and/or synthetic high-potency sweetener compositions with improved temporal profile and/or flavor profile, methods for their formulation, and uses |
| BRPI0914871B1 (pt) | 2008-06-20 | 2018-12-11 | Givaudan Sa | ingrediente de aumento de sal, seu processo de formação a partir do hidrolisado de material de planta de espinafre, produto alimentício, composição flavorizante para produtos alimentícios e método de provisão de um produto alimentício com salinidade aumentada |
| JP2011528321A (ja) | 2008-06-21 | 2011-11-17 | ケンバー,エルエルシー | ニュートリゲノミクス方法および組成 |
| JP5452893B2 (ja) | 2008-06-25 | 2014-03-26 | 小川香料株式会社 | カリウム塩又はカリウム塩含有飲食品の呈味改善剤 |
| ES2464459T3 (es) | 2008-06-25 | 2014-06-02 | H. Lundbeck A/S | Modulación del sistema receptor Trpv:receptor de dominio Vps 10p para el tratamiento del dolor |
| US8808768B2 (en) | 2008-07-21 | 2014-08-19 | Kailash Chandra Agarwal | Development of biochemically standardized extracts from fresh rhizomes of turmeric (Curcuma longa) for treatment of diseases caused by hyperuricemia |
| CN101318985A (zh) | 2008-07-23 | 2008-12-10 | 谢佳良 | 一种熊果酸的制备方法及其产品和应用 |
| US20100034944A1 (en) | 2008-08-06 | 2010-02-11 | Martha Lubenova Beyazova | Use of Avocado Derivatives in Flavor Applications |
| WO2010015260A2 (en) | 2008-08-07 | 2010-02-11 | Neurokey A/S | Administration by infusion for the treatment of ischemic effects |
| KR100995839B1 (ko) | 2008-08-08 | 2010-11-22 | 주식회사 아이토비 | 멀티미디어 디지털 콘텐츠의 축약정보 추출시스템과 축약 정보를 활용한 다중 멀티미디어 콘텐츠 디스플레이 시스템 및 그 방법 |
| MX2008010606A (es) | 2008-08-18 | 2010-02-17 | Integradora Bravo S A De C V | Composiciones fitosanitarias potenciadas con aceites vegetales crudos o sus derivados, y uso de las mismas para el control de plagas. |
| ES2612731T3 (es) | 2008-08-19 | 2017-05-18 | Janssen Pharmaceutica Nv | Antagonistas de receptores al frío de mentol |
| US20110217251A1 (en) * | 2008-09-08 | 2011-09-08 | Shai Meretzki | Therapeutic compositions comprising polyhydroxyltate fatty alcohol derivatives and uses thereof |
| AU2008221548A1 (en) | 2008-09-19 | 2010-04-08 | Greentaste Pty Ltd | Method For and Composition of Excipient Suitable for Use in Herbal Formulations and Formulations Derived Therefrom |
| WO2010036878A1 (en) | 2008-09-26 | 2010-04-01 | The Trustees Of Columbia University In The City Of New York | Use of trpv1 receptor agonists in cervical pain and labor |
| US20110237674A1 (en) | 2008-10-16 | 2011-09-29 | Novartis Ag | Topical nsaid compositions having sensate component |
| US20100099766A1 (en) | 2008-10-16 | 2010-04-22 | Novartis Ag | Topical NSAID compositions having sensate component |
| JP2010094081A (ja) | 2008-10-17 | 2010-04-30 | Kao Corp | 飲食品組成物 |
| JP5376629B2 (ja) | 2008-10-24 | 2013-12-25 | 長谷川香料株式会社 | フレーバー劣化防止剤 |
| JP5159568B2 (ja) | 2008-11-07 | 2013-03-06 | 小林製薬株式会社 | ヒハツ抽出物を含有する飲食品組成物及びヒハツ抽出物含有飲食品組成物の味改善方法 |
| US8709391B2 (en) | 2008-11-26 | 2014-04-29 | Board Of Regents Of The University Of Texas System | Family of pain producing substances and methods to produce novel analgesic drugs |
| WO2010078392A2 (en) | 2008-12-31 | 2010-07-08 | Novozymes North America, Inc. | Processes of producing fermentation products |
| WO2010092467A1 (en) | 2009-02-13 | 2010-08-19 | Carlo Ghisalberti | Medicament comprising terpenoid cholinesterase inhibitor for treatment of dismotility disorder |
| EP2404172A1 (en) * | 2009-03-06 | 2012-01-11 | Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke | Methods for isolating agonists and antagonists of taste receptors |
| WO2010107020A1 (ja) * | 2009-03-16 | 2010-09-23 | キリン協和フーズ株式会社 | 食塩味増強剤 |
| WO2010108542A1 (en) | 2009-03-25 | 2010-09-30 | Nestec S.A. | A natural taste enhancing savoury base and a process for its preparation |
| KR100987236B1 (ko) | 2009-03-31 | 2010-10-12 | 충남대학교산학협력단 | 항산화 활성을 갖는 음양곽 건조분말 또는 이의 추출물을 함유하는 조성물 |
| KR20100109207A (ko) | 2009-03-31 | 2010-10-08 | 충남대학교산학협력단 | 항산화 활성을 갖는 음양곽 건조분말 또는 이의 추출물을 이용한 동물의 사육방법 |
| US9060943B2 (en) | 2009-04-09 | 2015-06-23 | Symrise Ag | Compositions comprising trans-tert-butyl cyclohexanol as skin irritation-reducing agent |
| CN101862312A (zh) | 2009-04-14 | 2010-10-20 | 中国中医科学院中药研究所 | 6-姜酚的新用途 |
| US8962057B2 (en) | 2009-04-29 | 2015-02-24 | The Procter & Gamble Company | Methods for improving taste and oral care compositions with improved taste |
| US8980223B2 (en) | 2009-05-07 | 2015-03-17 | University Of Cincinnati | Methods of preventing ischemic injury using peripheral nociceptive stimulation |
| EP2253226B1 (de) | 2009-05-15 | 2015-07-15 | Leibniz-Institut für Pflanzenbiochemie (IPB) | Verwendung von Hydroxyflavan-Derivaten zur Geschmacksmodifizierung |
| JP5593641B2 (ja) * | 2009-06-26 | 2014-09-24 | 味の素株式会社 | 減塩飲食品用組成物 |
| KR101140156B1 (ko) | 2009-07-02 | 2012-05-02 | (주)죽력원 | 뽕잎을 이용한 기능성 소금의 제조방법 |
| JP2011030562A (ja) | 2009-07-07 | 2011-02-17 | Seinan Jidosha Kogyo Kk | ストレス性刺激による魚類生殖腺の雄化誘導方法 |
| JP6205133B2 (ja) | 2009-07-10 | 2017-09-27 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー |
| DE102009027744A1 (de) | 2009-07-15 | 2011-01-20 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Prekursor-Verbindungen von Süßrezeptor-Antagonisten zur Prävention oder Behandlung von Krankheiten |
| KR101181216B1 (ko) | 2009-07-29 | 2012-09-07 | 한국생명공학연구원 | 오수유 추출물, 이의 분획물 또는 퀴놀론 알칼로이드계 화합물을 포함하는 약학 조성물 |
| JP4845067B2 (ja) | 2009-09-01 | 2011-12-28 | 国立大学法人奈良女子大学 | 塩味増強剤及び塩味増強方法 |
| CN102021106B (zh) | 2009-09-18 | 2012-11-21 | 劲牌有限公司 | 一种中药保健酒及其生产工艺 |
| JP5739343B2 (ja) | 2009-10-02 | 2015-06-24 | ハウス食品グループ本社株式会社 | 塩味が補強又は増強された食品組成物及び異味が抑制された塩化カリウム含有組成物 |
| CN101696377B (zh) | 2009-11-04 | 2012-10-31 | 天津市亚天商贸有限公司 | 山楂干红酒的制备方法 |
| EP2509444A2 (en) | 2009-11-26 | 2012-10-17 | D.Xign | Appetite regulating dietary supplement |
| JP5639758B2 (ja) | 2009-12-22 | 2014-12-10 | 小川香料株式会社 | カリウム塩又はカリウム塩含有飲食品の呈味改善剤 |
| CA2788717A1 (en) * | 2010-02-04 | 2011-08-11 | Monell Chemical Senses Center | Compounds and methods for enhancing salty taste |
| US9277748B2 (en) | 2010-03-12 | 2016-03-08 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Agonist/antagonist compositions and methods of use |
| US20130039956A1 (en) | 2010-03-15 | 2013-02-14 | Ulrich Dietz | Use of nitrocarboxylic acids for the treatment, diagnosis and prophylaxis of aggressive healing patterns |
| EP2549891A4 (en) | 2010-03-23 | 2015-01-07 | Jeffrey Walters | TEXTURAL AND TASTE AMPLIFIERS AND ITS USE IN FOOD MANUFACTURE |
| JP5869229B2 (ja) | 2010-04-08 | 2016-02-24 | 高砂香料工業株式会社 | 塩味増強剤およびこれを含む昆布エキス |
| CN102210441A (zh) | 2010-04-12 | 2011-10-12 | 王晓鹏 | 一种食用鲜咸调味剂的制作技术 |
| US8053007B2 (en) * | 2010-04-13 | 2011-11-08 | Mark Innocenzi | Compositions and methods for fortifying a base food to contain the complete nutritional value of a standard equivalent unit of the nutritional value of one serving of fruits and vegetables (“SFV”) for human consumption |
| KR20130055595A (ko) * | 2010-04-15 | 2013-05-28 | 크로모셀 코포레이션 | 쓴맛을 감소시키거나 제거하기 위한 화합물, 조성물 및 방법 |
| JP5733737B2 (ja) | 2010-06-11 | 2015-06-10 | 長谷川香料株式会社 | 塩味増強剤組成物 |
| KR100987630B1 (ko) | 2010-07-01 | 2010-10-13 | 주식회사 아이씨푸드 | 소금대체재 및 그 제조방법 |
| KR101224873B1 (ko) | 2010-07-12 | 2013-01-22 | 한국식품연구원 | 발효 생강의 제조방법 |
| US20120027693A1 (en) | 2010-07-27 | 2012-02-02 | Bean Bruce P | Methods and compositions for preventing and relieving muscle cramps and for recovery from neuromuscular irritability and fatigue following exercise |
| JP2012025719A (ja) | 2010-07-28 | 2012-02-09 | Morinaga Milk Ind Co Ltd | プロトンポンプ阻害剤 |
| US20120034368A1 (en) * | 2010-08-06 | 2012-02-09 | Matsutani Chemical Industry Co., Ltd. | Method for improving salty taste of food or beverage and salty taste improving agent |
| CN102396758A (zh) | 2010-09-13 | 2012-04-04 | 李全能 | 一种具有多功能保健功能的饮料 |
| US20130302497A1 (en) | 2010-09-13 | 2013-11-14 | Givaudan S.A. | Taste Enhancement |
| CN101949904A (zh) | 2010-09-22 | 2011-01-19 | 中国烟草总公司郑州烟草研究院 | 一种测定烟用香原料白芷酊中欧前胡素含量的方法 |
| US20140088056A1 (en) | 2010-09-28 | 2014-03-27 | President And Fellows Of Harvard College | Cardiac glycosides are potent inhibitors of interferon-beta gene expression |
| CN101999627A (zh) | 2010-09-29 | 2011-04-06 | 重庆合川盐化工业有限公司 | 火锅调味盐 |
| WO2012060845A1 (en) | 2010-11-05 | 2012-05-10 | University Of Cincinnati | Methods of preventing ischemic injury using peripheral nociceptive stimulation |
| CN102058082B (zh) | 2010-11-22 | 2012-10-03 | 晨光生物科技集团股份有限公司 | 一种花椒有效成分的高效提取分离工艺 |
| CN101974399A (zh) | 2010-11-24 | 2011-02-16 | 曹光荣 | 一种功能性白酒及其制备方法 |
| KR101253041B1 (ko) | 2010-12-03 | 2013-04-10 | 송인상 | 약용작물을 이용한 가공소금의 제조방법 |
| WO2012098281A2 (es) | 2011-01-19 | 2012-07-26 | Universidad Miguel Hernández De Elche | Péptidos moduladores de receptores trp y sus usos |
| KR101324926B1 (ko) | 2011-01-28 | 2013-11-01 | 계명대학교 산학협력단 | 생강 추출물 제조방법 및 이에 따른 생강 추출물 |
| KR20120090359A (ko) | 2011-02-07 | 2012-08-17 | 한국식품연구원 | 생강에서 진지베린 성분을 추출하는 방법 |
| US8865741B2 (en) | 2011-02-18 | 2014-10-21 | Asana Biosciences, Llc | Aminoindane compounds and use thereof in treating pain |
| EP2684468A4 (en) | 2011-03-07 | 2014-08-27 | Ajinomoto Kk | EXTENDER OF SALTY TASTE |
| US8840938B2 (en) | 2011-04-13 | 2014-09-23 | W. Matthew Warnock | Bioavailability enhancing composition |
| JP5872187B2 (ja) * | 2011-05-17 | 2016-03-01 | 小川香料株式会社 | 塩味増強剤 |
| KR20130003452A (ko) | 2011-06-30 | 2013-01-09 | 목포대학교산학협력단 | 저염 소금 제조방법 |
| WO2013009827A1 (en) | 2011-07-13 | 2013-01-17 | Tempero Pharmaceuticals, Inc. | Methods of treatment |
| JP2013018764A (ja) | 2011-07-14 | 2013-01-31 | Kao Corp | 上皮型ナトリウムチャネル活性化剤 |
| CN102326768B (zh) | 2011-07-29 | 2013-07-31 | 天津春发生物科技集团有限公司 | 一种咸味香精 |
| US11096408B2 (en) | 2011-08-26 | 2021-08-24 | Mitsubishi Corporation Life Sciences Limited | Yeast extract having taste-enhancing effect |
| EP2753317B1 (en) | 2011-09-06 | 2020-02-26 | CuRNA, Inc. | TREATMENT OF DISEASES RELATED TO ALPHA SUBUNITS OF SODIUM CHANNELS, VOLTAGE-GATED (SCNxA) WITH SMALL MOLECULES |
| EP2578210A1 (en) | 2011-10-05 | 2013-04-10 | ATB Innovation Ltd. | Rottlerin for the treatment of pulmonary hypertension and related diseases and disorders |
| WO2013052844A1 (en) | 2011-10-07 | 2013-04-11 | Pulmatrix, Inc. | Methods for treating and diagnosing respiratory tract infections |
| CA2852380A1 (en) | 2011-10-20 | 2013-04-25 | Chromocell Corporation | Compounds, compositions, and methods for reducing or eliminating bitter taste |
| EP2771320B1 (en) | 2011-10-24 | 2016-06-22 | Endo Pharmaceuticals Inc. | Cyclohexylamines |
| GB201118481D0 (en) | 2011-10-26 | 2011-12-07 | Givaudan Sa | Organic compounds |
| GB2496898B (en) | 2011-11-25 | 2020-10-28 | Petroliam Nasional Berhad Petronas | Corrosion inhibition |
| KR20130076905A (ko) | 2011-11-28 | 2013-07-09 | 김광순 | 식품용 자연 조미료 맛을 내는 건조 함초. 멸치소금 제조방법 |
| EP2789246B1 (en) | 2011-12-06 | 2019-03-13 | Nippon Suisan Kaisha, Ltd. | Taste-improving agent and taste improvement method for a foodstuff |
| CN102423352B (zh) | 2011-12-13 | 2013-10-09 | 广东众生药业股份有限公司 | 一种治疗心脑血管疾病的中药颗粒剂的制备方法 |
| JP5906541B2 (ja) | 2011-12-22 | 2016-04-20 | 国立大学法人高知大学 | ジンゲロール含有組成物 |
| UA112671C2 (uk) | 2011-12-23 | 2016-10-10 | Нестек С.А. | Спосіб одержання смако-ароматичної композиції зі смаком і ароматом умамі |
| KR101268782B1 (ko) | 2011-12-29 | 2013-05-29 | 세종대학교산학협력단 | 버섯 균사체 세포벽에 포집된 소금 및 이를 포함하는 면류의 제조방법 |
| WO2013103031A1 (ja) | 2012-01-06 | 2013-07-11 | 株式会社カネカ | 塩味増強剤 |
| JP3179252U (ja) | 2012-07-13 | 2012-10-25 | 株式会社美多加堂 | 加工食品用粉末食塩 |
| CN102763829A (zh) * | 2012-07-24 | 2012-11-07 | 朱建辉 | 辣糟卤生产工艺 |
| CN102987128A (zh) | 2012-10-10 | 2013-03-27 | 合肥永生禽业有限责任公司 | 一种槐花猪饲料添加剂 |
| CN102987068A (zh) | 2012-10-10 | 2013-03-27 | 合肥永生禽业有限责任公司 | 一种能增强食欲的猪饲料及其制备方法 |
| CN102987123A (zh) | 2012-10-10 | 2013-03-27 | 合肥永生禽业有限责任公司 | 一种蚕沙猪饲料及其制备方法 |
| CN102934746B (zh) | 2012-10-13 | 2013-09-25 | 安徽泗县成安牧业科技有限公司 | 发酵植物叶种猪饲料 |
| CN102907615A (zh) | 2012-10-25 | 2013-02-06 | 沈阳田东科研有限公司 | 一种鸡汤焖面条的制作方法 |
| CN102948645B (zh) | 2012-10-29 | 2013-11-06 | 合肥市益农养殖有限公司 | 一种桑葚鸭饲料及其制备方法 |
| CN102972558A (zh) | 2012-12-05 | 2013-03-20 | 袁辉 | 一种清热降压茶的加工工艺 |
| CN102972552A (zh) | 2012-12-05 | 2013-03-20 | 袁辉 | 一种清热降压茶 |
| CN111557432B (zh) * | 2013-02-08 | 2023-08-04 | 通用磨坊公司 | 低钠食品 |
| CN103141575A (zh) | 2013-03-15 | 2013-06-12 | 南京师范大学 | 一种富含血管紧张素转化酶抑制肽山楂酸乳的制备方法 |
-
2014
- 2014-02-07 CN CN202010439403.1A patent/CN111557432B/zh active Active
- 2014-02-07 WO PCT/US2014/015192 patent/WO2014124191A1/en not_active Ceased
- 2014-02-07 EP EP14705944.8A patent/EP2953934B1/en active Active
- 2014-02-07 PT PT201756178T patent/PT3732994T/pt unknown
- 2014-02-07 CA CA2900707A patent/CA2900707C/en active Active
- 2014-02-07 WO PCT/US2014/015240 patent/WO2014124220A1/en not_active Ceased
- 2014-02-07 WO PCT/US2014/015230 patent/WO2014124214A1/en not_active Ceased
- 2014-02-07 WO PCT/US2014/015211 patent/WO2014124201A1/en not_active Ceased
- 2014-02-07 ES ES14705459.7T patent/ES2675215T3/es active Active
- 2014-02-07 WO PCT/US2014/015239 patent/WO2014124219A1/en not_active Ceased
- 2014-02-07 US US14/766,557 patent/US11540539B2/en active Active
- 2014-02-07 ES ES18201716T patent/ES2925071T3/es active Active
- 2014-02-07 WO PCT/US2014/015207 patent/WO2014124198A1/en not_active Ceased
- 2014-02-07 DK DK18164825.4T patent/DK3366677T3/da active
- 2014-02-07 ES ES14705944.8T patent/ES2671954T3/es active Active
- 2014-02-07 CA CA3081195A patent/CA3081195C/en active Active
- 2014-02-07 BR BR112015018948A patent/BR112015018948A2/pt not_active Application Discontinuation
- 2014-02-07 DK DK14705944.8T patent/DK2953934T3/en active
- 2014-02-07 EP EP14705458.9A patent/EP2984073B1/en active Active
- 2014-02-07 ES ES20175617T patent/ES2936634T3/es active Active
- 2014-02-07 DK DK20175617.8T patent/DK3732994T3/da active
- 2014-02-07 EP EP20175617.8A patent/EP3732994B1/en active Active
- 2014-02-07 ES ES14705945.5T patent/ES2675018T3/es active Active
- 2014-02-07 PT PT181648254T patent/PT3366677T/pt unknown
- 2014-02-07 BR BR112015018847A patent/BR112015018847A2/pt not_active Application Discontinuation
- 2014-02-07 CN CN201480019810.XA patent/CN105164245B/zh active Active
- 2014-02-07 PT PT147059448T patent/PT2953934T/pt unknown
- 2014-02-07 JP JP2015557084A patent/JP2016509830A/ja active Pending
- 2014-02-07 WO PCT/US2014/015223 patent/WO2014124209A1/en not_active Ceased
- 2014-02-07 DK DK14705459.7T patent/DK2956440T3/en active
- 2014-02-07 EP EP18201716.0A patent/EP3466930B1/en active Active
- 2014-02-07 FI FIEP20175617.8T patent/FI3732994T3/fi active
- 2014-02-07 WO PCT/US2014/015227 patent/WO2014124212A1/en not_active Ceased
- 2014-02-07 JP JP2015557085A patent/JP2016506747A/ja active Pending
- 2014-02-07 DK DK14705945.5T patent/DK2954037T3/en active
- 2014-02-07 ES ES14705458T patent/ES2704880T3/es active Active
- 2014-02-07 EP EP18164825.4A patent/EP3366677B1/en active Active
- 2014-02-07 CN CN201810631692.8A patent/CN108902893B/zh active Active
- 2014-02-07 WO PCT/US2014/015234 patent/WO2014124216A1/en not_active Ceased
- 2014-02-07 CN CN201480019853.8A patent/CN105189460B/zh active Active
- 2014-02-07 PT PT14705458T patent/PT2984073T/pt unknown
- 2014-02-07 EP EP14705459.7A patent/EP2956440B1/en active Active
- 2014-02-07 PT PT147054597T patent/PT2956440T/pt unknown
- 2014-02-07 PT PT147059455T patent/PT2954037T/pt unknown
- 2014-02-07 WO PCT/US2014/015216 patent/WO2014124205A1/en not_active Ceased
- 2014-02-07 CA CA2900710A patent/CA2900710C/en active Active
- 2014-02-07 WO PCT/US2014/015200 patent/WO2014124193A1/en not_active Ceased
- 2014-02-07 PT PT182017160T patent/PT3466930T/pt unknown
- 2014-02-07 WO PCT/US2014/015220 patent/WO2014124207A1/en not_active Ceased
- 2014-02-07 DK DK18201716.0T patent/DK3466930T3/da active
- 2014-02-07 DK DK14705458.9T patent/DK2984073T3/en active
- 2014-02-07 EP EP14705945.5A patent/EP2954037B1/en active Active
- 2014-02-07 ES ES18164825T patent/ES2831028T3/es active Active
- 2014-02-07 WO PCT/US2014/015244 patent/WO2014124222A1/en not_active Ceased
-
2015
- 2015-08-07 US US14/820,891 patent/US10159268B2/en active Active
-
2018
- 2018-11-21 US US16/197,550 patent/US20190090520A1/en not_active Abandoned
- 2018-12-12 JP JP2018232143A patent/JP7188999B2/ja active Active
-
2019
- 2019-07-16 JP JP2019130844A patent/JP6982599B2/ja not_active Expired - Fee Related
-
2020
- 2020-05-18 US US16/877,126 patent/US20200281236A1/en not_active Abandoned
-
2021
- 2021-11-19 JP JP2021188840A patent/JP2022027792A/ja not_active Ceased
-
2024
- 2024-01-22 JP JP2024007208A patent/JP2024045277A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010124905A1 (en) * | 2009-04-29 | 2010-11-04 | Akzo Nobel Chemicals International B.V. | Process to prepare a low-sodium salt product, product obtainable thereby and the use thereof |
Non-Patent Citations (4)
| Title |
|---|
| ANJAN REDDY K ET AL: "REDUCING THE SODIUM CONTENT OF FOODS: A REVIEW", JOURNAL OF FOOD PROTECTION, INTERNATIONAL ASSOCIATION FOR FOOD PROTECTION, US, vol. 54, no. 2, 1 January 1991 (1991-01-01), pages 138 - 150, XP008078157, ISSN: 0362-028X * |
| BEST D: "Compensating for sodium: the low-salt solution", PREPARED FOODS, GORMAN PUB., CHICAGO, IL, US, vol. 158, no. 22, 1 February 1989 (1989-02-01), pages 97 - 98, XP008098474, ISSN: 0747-2536 * |
| DESMOND ET AL: "Reducing salt: A challenge for the meat industry", MEAT SCIENCE, ELSEVIER SCIENCE, GB, vol. 74, no. 1, 1 September 2006 (2006-09-01), pages 188 - 196, XP027989851, ISSN: 0309-1740, [retrieved on 20060901] * |
| GYU-HEE LEE: "A salt substitute with low sodium content from plant aqueous extracts", FOOD RESEARCH INTERNATIONAL, vol. 44, no. 2, 1 March 2011 (2011-03-01), pages 537 - 543, XP055113729, ISSN: 0963-9969, DOI: 10.1016/j.foodres.2010.11.018 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021094268A1 (en) * | 2019-11-11 | 2021-05-20 | Firmenich Sa | Gingerol compounds and their use as flavor modifiers |
| WO2021175751A1 (en) * | 2020-03-05 | 2021-09-10 | Firmenich Sa | 11-oxo-cucurbitanes and their use as flavor modifiers |
| WO2022214275A1 (en) * | 2021-04-06 | 2022-10-13 | Firmenich Sa | Use of gingerdiol compounds to enhance flavor |
| US20240099343A1 (en) * | 2021-04-06 | 2024-03-28 | Firmenich Sa | Use of gingerdiol compounds to enhance flavor |
| CN113582981A (zh) * | 2021-07-08 | 2021-11-02 | 中国科学院昆明植物研究所 | 一类新颖二芳基庚烷-黄烷酮杂合体及其药物组合物和应用 |
| CN113582981B (zh) * | 2021-07-08 | 2023-09-05 | 中国科学院昆明植物研究所 | 一类新颖二芳基庚烷-黄烷酮杂合体及其药物组合物和应用 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2956440B1 (en) | Reduced sodium food products | |
| HK40026880A (en) | Reduced sodium food products | |
| HK40026880B (zh) | 低钠食品 | |
| HK1257861A1 (en) | Reduced sodium food products | |
| HK1257861B (en) | Reduced sodium food products |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14705458 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2014705458 Country of ref document: EP |